S (2010-2017)

STUDIES ON CONDITIONS and RELATED ARTICLES 2010-2017

+Studies in 2000-2009 List
*Studies in Pre-2000 List

SAFETY AS A MEDICINE*+
SAFETY-ADULTERANTS/CONTAMINANTS*+
SCHINZEL-GIEDION SYNDROME (See News Articles 2010-2017)
SCHISTOSOMA INFECTION +
SCHIZOPHRENIA/MENTAL DISORDERS*+
SCLERODERMA +
SEBACEOUS GLANDS + (Produce Skin Oils)
SEBORRHEA
SEPTIC SHOCK/SEPSIS*+
SHINGLES (See News Articles 2010-2017)
SICKLE CELL DISEASE +
SINUSITIS (See 2000-2009)
SLEEP APNEA +
SLEEPING SICKNESS/TRYPANOSOMIASIS* (See Also CHAGAS DISEASE)
SLEEP MODULATION*+
SMALLPOX + (See Also COW POX [not good news])
SMELL/ODOR DETECTION +
SMOKED CANNABIS AS A MEDICATION*+ (See Also METHODS OF USE-SMOKING)
SOCIAL ADJUSTMENT/BEHAVIOR*+
SOCIAL MEDIA/INTERNET
SPACEFLIGHT/OUTER SPACE
SPASTICITY*+
SPINAL CORD INJURY*+
SPINOCEREBELLAR ATAXIA/SCA (Inherited Neurodegenerative Disorder. See Also ATAXIA)
SPLEEN*+
SPORTS (see Also EXERCISE)
STEM CELLS +
STIFF-PERSON SYNDROME/HYPEREKPLEXIA DISEASE +
STRAIN INFORMATION (Until Researchers Pay Attention To What Strains They Are Using, They Will Never Get Consistent Results!)
STRESS + (See Also ANXIETY, POST TRAUMATIC STRESS DISORDER)
STORAGE of CANNABIS*+ (Most Are Old, But Questions On Storage Come Up Often!)
STROKE*+ (See Also PERINATAL HYPOXIC-ISCHEMIC INJURY)
STUTTERING + (See News Articles 2010-2017)
SUICIDE +
SYSTEMIC MASTOCYTOSIS
SYSTEMIC SCLEROSIS
top


SAFETY AS A MEDICINE
Information for Health Care Professionals- Marihuana (marijuana, cannabis) dried plant for administration by ingestion or other means (Health Canada) (full–2010) http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php
Drug Harms in the UK (full–2010) http://www.scribd.com/doc/41349905/Alcohol-Lancet-2010
Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use (abst–2010)
http://www.ncbi.nlm.nih.gov/pubmed/20565525
Ocular Hypotensive Efficacy and Safety of Oral Palmytoilethanolamide (Visimast®): Clinical Study (abst–2010) http://iovs.arvojournals.org/article.aspx?articleid=2369941&resultClick=1
Harms associated with psychoactive substances: findings of the UK National Drug Survey (abst–2010) http://jop.sagepub.com/cgi/content/abstract/24/2/147?rss=1
A summary of the health harms of drugs – Section 5 Cannabis (full–2011) http://www.nta.nhs.uk/uploads/healthharmsfinal-v1.pdf
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/22129319/abstract/Safety_and_Side_Effects_of_Cannabidiol_a_Cannabis_sativa_Constituent
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent (full-2011) http://www.medicinalgenomics.com/wp-content/uploads/2013/01/Bergamaschi_2011.pdf
Role of Cannabinoids in Multiple Sclerosis (link to PDF – 2011) http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.659.8269&rank=26
Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety (link to download–2011) http://journals.sagepub.com/doi/abs/10.1177/1479972310391283
Annual Causes of Death in the United States (article–2011) http://drugwarfacts.org/cms/?q=node/30
Prescribing Cannabis for Harm Reduction (full–2012) http://www.harmreductionjournal.com/content/pdf/1477-7517-9-1.pdf
Medical Marijuana: Clearing Away the Smoke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/
Synthetic cannabinoid and marijuana exposures reported to poison centers (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22859662
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22716148
Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22509986
Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107777/
The pharmacologic and clinical effects of medical cannabis (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/phar.1187/full
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? (abst–2013)  http://www.ncbi.nlm.nih.gov/pubmed/24084047
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945037/
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24160757
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review (full–2013) http://www.tandfonline.com/doi/full/10.3109/03602532.2013.849268
(Re)introducing medicinal cannabis (article–2013) https://www.mja.com.au/journal/2013/199/11/reintroducing-medicinal-cannabis
Anticipated Medical Effects on Children From Legalization of Marijuana in Colorado and Washington State (abst+1st page–2013) http://archpedi.jamanetwork.com/article.aspx?articleid=1691419&resultClick=3
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23369054
Physical harm due to chronic substance use (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23542091
Prescribing smoked cannabis for chronic noncancer pain: Preliminary recommendations (full–2014) http://www.cfp.ca/content/60/12/1083.long
Physicians as gatekeepers in the use of medical marijuana (full–2014) http://www.jaapl.org/content/39/4/460.long
The Legalization of Marijuana in Colorado: The Impact. Rocky Mountain HIDTA. The Impact (full–2014) http://www.rmhidta.org/html/August%202014%20Legalization%20of%20MJ%20in%20Colorado%20the%20Impact.pdf
Inhaled medicinal cannabis and the immunocompromised patient (full–2014) MASSC
Cannabidiol: Promise and Pitfalls (full–2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189631/
A new method of cannabis ingestion: The dangers of dabs? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24930049
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24943098
Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25035121
Re-branding cannabis: the next generation of chronic pain medicine? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25537695
THE EFFECT OF EPIDIOLEX (CANNABIDIOL) ON SERUM LEVELS OF CONCOMITANT ANTI-EPILEPTIC DRUGS IN CHILDREN AND YOUNG ADULTS WITH TREATMENT-RESISTANT EPILEPSY IN AN EXPANDED ACCESS PROGRAM (abst–2014) https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868391#sthash.uxbwgudh.dpuf
Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25634572
top
The cannabis conundrum: Thinking outside the THC box (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/jcph.511/full
Notes from the Field: Death Following Ingestion of an Edible Marijuana Product-Colorado, March 2014 (full–2015) http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6428a6.htm
Cannabis and Cannabinoids–for health professionals (PDQ®) (full–2015) http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/all
Cannabis and Cannabinoids (PDQ®): Patient Version (full–2015) http://www.ncbi.nlm.nih.gov/books/NBK65875/
Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development (full–2015) http://www.hindawi.com/journals/ecam/2015/238482/
Mull it over: cannabis vaporizers and harm reduction (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/add.13139/full
No smoke, no fire: What the initial literature suggests regarding vapourized cannabis and respiratory risk (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456813/
Cannabinoids in the management of chronic pain: a front line clinical perspective (full–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0059/jbcpp-2015-0059.xml
Perceived risk of regular cannabis use in the United States from 2002 to 2012: Differences by sex, age, and race/ethnicity (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361312/
Cannabis Allergy: What do We Know Anno 2015 (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26178655
Cannabis Allergy: What do We Know Anno 2015 (full–2015) http://link.springer.com/article/10.1007%2Fs00005-015-0352-z
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26517407
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/ Responsible and controlled use: Older cannabis users and harm reduction (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25911027
Responsible and controlled use: Older cannabis users and harm reduction (full–2015) http://www.ijdp.org/article/S0955-3959(15)00075-4/fulltext
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia (abst–2015)
http://link.springer.com/article/10.1007/s00213-015-3889-y/fulltext.html
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9- tetrahydrocannabinol in older persons with dementia (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480847/
European rating of drug harms (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25922421
Marijuana: A Time-Honored but Untested Treatment for Epilepsy (full–2015) https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/divclasstitlemarijuana-a-time-honored-but-untested-treatment-forepilepsydiv/DDEDDD9EAA09918D3D69CC7CA047AE5C/core-reader
Phytocannabinoids and epilepsy (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12235/full
Cannabinoids and Epilepsy (full–2015) http://link.springer.com/article/10.1007%2Fs13311-015-0375-5
Safety of oral dronabinol during opioid withdrawal in humans (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26483357
Safety of oral dronabinol during opioid withdrawal in humans (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663169/
Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/25759401
Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample (full–2015) http://journals.sagepub.com/doi/full/10.1177/0269881115574493
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS) (link to PDF–2015) http://www.jpain.org/article/S1526-5900%2815%2900837-8/abstract
Half-Baked – The Retail Promotion of Marijuana Edibles (article–2015) http://www.nejm.org/doi/full/10.1056/NEJMp1416014
Cannabis conundrum: Evidence of harm?: Opposition to marijuana use is often rooted in arguments about the drug’s harm to children and adults, but the scientific evidence is seldom clear-cut (article–2015) http://onlinelibrary.wiley.com/doi/10.1002/cncy.21516/full
How beneficial is vaping cannabis to respiratory health compared to smoking? (article-2015) http://onlinelibrary.wiley.com/doi/10.1111/add.13075/full
Peaceful feeling, or up in smoke? Medical marijuana in medicolegal context (article–2015) http://www.mdedge.com/currentpsychiatry/article/102099/practice-management/peaceful-feeling-orsmoke-medical-marijuana
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products (letter-2015) http://jama.jamanetwork.com/article.aspx?articleid=2338239
top
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial (abst–2015) http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2815%2900379-8/abstract
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials (full–2015) http://tinyurl.com/nl9g6x6
A safer alternative: Cannabis substitution as harm reduction (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25919477
Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study (abst–2015) http://link.springer.com/article/10.1007/s10072-015-2392-x
Prescribing medical cannabis in Canada: Are we being too cautious? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26451996
Merck Manual – Marijuana (Cannabis) Professional version (full–2016) http://www.merckmanuals.com/professional/special-subjects/recreational-drugs-and-intoxicants/marijuanacannabis
Merck Manual – Marijuana (Cannabis) Consumer version (full–2016) http://www.merckmanuals.com/home/special-subjects/recreational-drugs-and-intoxicants/marijuana
Cannabinoids for pediatric epilepsy? Up in smoke or real science? (full – 2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729003/
AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. (full – 2016) http://www.nature.com/tp/journal/v6/n2/full/tp2015219a.html
Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway. (full – 2016) http://jpet.aspetjournals.org/content/early/2016/05/18/jpet.116.232561.long
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience (abst–2016) http://www.sciencedirect.com/science/article/pii/S1059131116000054
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience (full–2016) http://www.sciencedirect.com/science/article/pii/S1059131116000054
Is the medical use of cannabis a therapeutic option for children? (full – 2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758425/
Minimal Physical Health Risk Associated With Long-term Cannabis Use—But Buyer Beware (full– 2016) http://jama.jamanetwork.com/article.aspx?articleid=2526619
Associations Between Cannabis Use and Physical Health Problems in Early Midlife (full – 2016) http://archpsyc.jamanetwork.com/article.aspx?articleid=2526003
Drug vaping applied to cannabis: Is “Cannavaping” a therapeutic alternative to marijuana? (full – 2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881394/
Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes (full – 2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00279/full
Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines (full – 2016) https://www.ncbi.nlm.nih.gov/books/NBK395789/
Marijuana – How Safe is it Really? (full – 2016) https://journals.mcmaster.ca/iScientist/article/download/1104/991
Medical cannabis use in Canada: vapourization and modes of delivery (full – 2016) https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-016-0119-9
Minnesota Pharmacists and Medical Cannabis: A Survey of Knowledge, Concerns, and Interest Prior to Program Launch (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083080/
Cannabis and Cannabinoids (PDQ®)Health Professional Version (full–2016) https://www.ncbi.nlm.nih.gov/books/NBK65755/
Evidence for Medicinal Use of Cannabis (article – 2016) http://www.physio-pedia.com/Evidence_for_Medicinal_Use_of_Cannabis
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26757043
Marijuana: Medical Applications, Recreational Use and Substance Abuse Disorders (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780123970459001336
Chapter 5 – Quality Control and Stability Assessment (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780128046463000059
Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain : A systematic review of randomized controlled studies. (scroll down for English version) (abst–2016) http://link.springer.com/article/10.1007%2Fs00482-015-0089-y
Plant-Derived and Endogenous Cannabinoids in Epilepsy (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26892745
Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26910181
Cannabinoids: Medical implications. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26912385
Cannabis – Position Paper of the German Respiratory Society (DGP) (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26935046
The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26889611
Qualitative research in Spanish cannabis social clubs: “The moment you enter the door, you are minimising the risks” (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27461986
Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms A Mile High (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27579692
Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/26809974
State of the evidence: Cannabinoids and cancer pain-A systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27863159
Alcohol and cannabis: Comparing their adverse health effects and regulatory regimes (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27908654
Rocky Mountain High: Preventing Cannabis-Related Injuries (1st page–2017) http://www.jenonline.org/article/S0099-1767(16)30339-7/abstract
top


SAFETY-ADULTERANTS/CONTAMINANTS
CUT, A Guide to the Adulterants, Bulking agents and other Contaminants found in illicit drugs (full–2010) http://www.cph.org.uk/publication/cut-a-guide-to-the-adulterants-bulking-agents-and-other-contaminants-found-in-illicit-drugs/
Too many mouldy joints – marijuana and chronic pulmonary aspergillosis (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103256/?tool=pubmed
Fatal alveolar haemorrhage following a “bang” of cannabis (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21943539
Talcum induced pneumoconiosis following inhalation of adulterated marijuana, a case report (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348083/
Determination of pesticide residues in cannabis smoke (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666265/
Hemoptysis in a young man smoking cannabis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23619207
Potential exposures associated with indoor marijuana growing operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24116667
Recurrent myopericarditis as a complication of Marijuana use (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921097/
Inhaled medicinal cannabis and the immunocompromised patient (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25216851
Determination of Herbicides Paraquat, Glyphosate, and Aminomethylphosphonic Acid in Marijuana Samples by Capillary Electrophoresis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25413634
Cannabis, Pesticides and Conflicting Laws: the Dilemma for Legalized States and Implications for Public Health (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24859075
Levels of selected metals in leaves of Cannabis sativa L. cultivated in Ethiopia (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503701/
Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing (link to PDF–2015) https://www.jstage.jst.go.jp/article/jts/40/6/40_797/_article
Dabble With Danger: A Case Of Severe Respiratory Failure Following Inhalation Of Butane Hash Oil (abst–2015) http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4596
False hashish without cannabis resin (abst–2015) http://www.ingentaconnect.com/search/article?option1=tka&value1=cannabinoid&sortDescending=true&sortField=prism_publicationDate&pageSize=10&index=24
Phytoaccumulation of Heavy Metals in Natural Vegetation at the Municipal Wastewater Site in Abbottabad, Pakistan (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26366840
Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00108/full
Drug vaping applied to cannabis: Is “Cannavaping” a therapeutic alternative to marijuana? (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881394/ Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00279/full
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues (full – 2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00309/full
Metagenomic analysis of medicinal Cannabis samples; pathogenic bacteria, toxigenic fungi, and beneficial microbes grow in culture-based yeast and mold tests (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089129/
Analysis of a commerical marijuana e-cigarette formulation (abst–2016) (This article has a delayed release and will be available in PMC on June 1, 2017) https://www.ncbi.nlm.nih.gov/pubmed/27059691
Acute intoxication of four individuals following use of the synthetic cannabinoid MABCHMINACA (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27227269
Alveolar haemorrhage following a cannabis water pipe (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27421143
Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA (full–2017) http://journals.sagepub.com/doi/abs/10.1177/0269881116684336?url_ver=Z39.88- 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences (link to download–2017) http://jpet.aspetjournals.org/content/early/2017/01/13/jpet.116.238717.long


SCHISTOSOMA INFECTION
Effects of anandamide on proliferation of and pErk expression in primary hepatic stellate cells of schistosome-induced liver fibrosis mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23663762
Upregulation of Cannabinoid Receptor-1 and Fibrotic Activation of Mouse Hepatic Stellate Cells during Schistosoma J. Infection: Role of NADPH Oxidase (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24657416
top


SCHIZOPHRENIA/MENTAL DISORDERS
Mixed mood disorder (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/228/?pagenum=2
Harm Reduction: Alcohol Use Disorder, Cannabis-induced Psychotic Disorder and a tale of two Hemp Oils, in a Patient diagnosed with a Cluster A & B Personality Disorders in Long Term Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/601/?pagenum=2
Do patients think cannabis causes schizophrenia? – A qualitative study on the causal beliefs of cannabis using patients with schizophrenia (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954921/?tool=pmcentrez
Reasons for illicit drug use in people with schizophrenia: Qualitative study (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999587/?tool=pubmed
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900481/?tool=pubmed
Therapeutical use of the cannabinoids in psychiatry (full–2010) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462010000500009&lng=en&nrm=iso&tlng=en
A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055343/?tool=pubmed
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2010.00144.x/full
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice (full–2010) http://ijnp.oxfordjournals.org/content/13/7/861.long
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283159/
Alterations in Metabotropic Glutamate Receptor 1a and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia (full-2010) http://ajp.psychiatryonline.org/article.aspx?articleID=102528&resultClick=1
Does intravenous {triangleup}9-tetrahydrocannabinol increase dopamine release? A SPET study (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed?term=20851843
Endocannabinoids and Schizophrenia (link to PDF–2010) http://www.mdpi.com/1424-8247/3/10/3101
Endocannabinoids and psychiatric disorders: the road ahead (article–2010) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516- 44462010000500003&lng=en&nrm=iso&tlng=en
Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis (editorial–2010) http://www.ajemjournal.com/article/S0735-6757%2810%2900394-3/abstract
Tardive Dystonia and the Use of Cannabis (letter-forum repost-2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/19854030
Brain cannabinoid CB2 receptor in schizophrenia (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/19931854
Attraction to cannabis among men with schizophrenia: a phenomenological study (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20420097
Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice (full–2011) http://www.nature.com/npp/journal/v36/n7/full/npp201134a.html
Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use (full–2011) http://www.hindawi.com/journals/sprt/2011/501726/
Gadolinium-HU-308-incorporated micelles (full–2011) http://www.ncbi.nlm.nih.gov/books/NBK54067/pdf/CB2R-Gd-Micelles.pdf
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Cannabis, COMT and psychotic experiences (full–2011) http://bjp.rcpsych.org/content/199/5/380.long
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186912/pdf/fnbeh-05-00063.pdf
The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156975/
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717343/
Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085576/
Cannabis with high cannabidiol content is associated with fewer psychotic experiences (full–2011) http://www.schres-journal.com/article/S0920-9964%2811%2900224-6/fulltext
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? (full–2011) http://www.lufg.com.au/files/media/Popular_intoxicants_what_lessons_can_be_learned.pdf
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids (full–2011) http://ijnp.oxfordjournals.org/content/14/5/631.long
Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice (full–2011) http://www.nature.com/npp/journal/v36/n7/full/npp201134a.html
The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives (full–2011) http://jop.sagepub.com/content/26/1/150.full.pdf+html
Cannabis use predicts shorter duration of untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study (full–2011) http://www.ajop.co.za/Journals/November2010/Original%20articles/Cannabis%20use.pdf
History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability (full–2011) http://jop.sagepub.com/content/26/1/144.long
top
Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21458498
Synthetic cannabinoid JWH-018 and psychosis: An explorative study (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21316162/abstract/Synthetic_cannabinoid_JWH_018_and_psychosis:_An_explorative_study_
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21278728
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Figure 1: n-3/n-6 PUFA dietary imbalance alters PUFAs level in mouse brain (charts–2011) http://www.nature.com/neuro/journal/v14/n3/fig_tab/nn.2736_F1.html
Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21087649
Endocannabinoid system dysfunction in mood and related disorders (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21916860
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21798112
Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21513772/abstract/Association_between_a_cannabinoid_receptor_gene__CNR1__polymorphism_and_cannabinoid_induced_alterations_of_the_auditory_event_related_P300_potential_
top
Prospective Study of Cannabis Use in Adolescents at Clinical High-Risk for Psychosis: Impact on Conversion to Psychosis and Functional Outcome (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459073/
Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong (full–2012) http://easap.asia/journal_file/1201_V22N1_p31.pdf
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/?tool=pubmed
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317922/
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the “Mirror Effect” of Schizophrenia (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457074/
Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts (full–2012) http://www.biomedcentral.com/1471-244X/12/112
Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392453/
A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional–motivational reactivity (full–2012) http://link.springer.com/article/10.1007/s00213-012-2785-y/fulltext.html
The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full-2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463751/
Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351574/
Cortical basket cell dysfunction in schizophrenia (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381305/
The endocannabinoid system and its role in schizophrenia: a systematic review of the literature (full-2012) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000600005&lng=en&nrm=iso&tlng=en
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23042808
Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions (link to PDF – 2012) http://www.eurekaselect.com/102835/article
The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydro-cannabinol and Cannabidiol in Rodent Models of Schizophrenia (link to PDF–2012) http://www.eurekaselect.com/102848/article
A critical review of the antipsychotic effects of Cannabidiol: 30 years of a translational investigation (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22716160
A critical review of the antipsychotic effects of Cannabidiol: 30 years of a translational investigation. (link to PDF–2012) http://www.eurekaselect.com/102849/article
Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (full-2012) http://onlinelibrary.wiley.com/doi/10.1002/dta.1425/full
Increased gray matter density in patients with schizophrenia and cannabis use: A voxel based morphometric study using DARTEL (abst–2012) http://www.sciencedirect.com/science/article/pii/S0920996412001740
Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22716146
Neurocognitive functioning and cannabis use in schizophrenia (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22716156
Anandamide dysfunction in prodromal and established psychosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22716147
Subjective and Physiological Effects of Oromucosal Sprays Containing Cannabinoids (Nabiximols): Potentials and Limitations for Psychosis Research (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22716155
Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice (abst–2012) http://www.springerlink.com/content/ur5784gm34782505/
Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22920733
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22831980
Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544397/
Cannabis and psychosis: what causes what? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544398/
Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0033548
An investigation into “two hit” effects of BDNF deficiency and young-adult cannabinoid receptor stimulation on prepulse inhibition regulation and memory in mice (full–2013) http://www.frontiersin.org/Journal/10.3389/fnbeh.2013.00149/full
The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0076635
“Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/hup.2312/full
Neuregulin-1 Impairs the Long-term Depression of Hippocampal Inhibitory Synapses by Facilitating the Degradation of Endocannabinoid 2-AG (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776056/
top
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717536/
What does a mouse tell us about neuregulin 1-cannabis interactions? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581817/
Peripheral endocannabinoid system dysregulation in first-episode psychosis (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828529/
The role of cannabinoid 1 receptor expressing interneurons in behavior (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946968/
Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/acps.12108/full
Creativity in cannabis-users and in drug addicts in maintenance treatment and in rehabilitation (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23359015
top
CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23422373
A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: Potential extinction enhancers (abst–2013) http://www.sciencedirect.com/science/article/pii/S002839081200247X
Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats (abst–2013) http://link.springer.com/article/10.1007/s00213-012-2839-1
Neonatal lipopolysaccharide treatment has long term effects on monoaminergic and cannabinoid receptors in the rat (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23389966
Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23414608
Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23518784
Neonatal lipopolysaccharide treatment has long-term effects on monoaminergic and cannabinoid receptors in the rat (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/syn.21640/abstract
Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse: A Case Report (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23670023
Quantification of endocannabinoids in postmortem brain of schizophrenic subjects (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23800614
Association of Single-Nucleotide Polymorphisms in the Cannabinoid Receptor 2 Gene with Schizophrenia in the Han Chinese Population (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23846977
Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: A time series analysis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23867051
Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23906663
Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24219803
Fatty acid ethanolamide levels are altered in borderline personality and complex post-traumatic stress disorders (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24253425
The endocannabinoid system and its possible role in neurobiology of psychiatric disorders (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24326750
Cannabidiol as a potential treatment for psychosis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24309088
The vital role of constitutive GPCR activity in the mesolimbic dopamine system (full–2014) http://www.ncbi.nlm.nih.gov/pubmed/24518399
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuro-psychiatric disorders (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/epi.12631/full
CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016688/
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915876/
top
Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders (full–2014) http://jpn.ca/wp-content/uploads/2014/12/39-6-140081.pdf
A controlled family study of cannabis users with and without psychosis (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319545/
Impaired Fear Memory Specificity Associated with Deficient Endocannabinoid Dependent Long-Term Plasticity (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023141/
Cannabinoid Transmission in the Prefrontal Cortex Bi-Phasically Controls Emotional Memory Formation via Functional Interactions with the Ventral Tegmental Area (full–2014) http://www.jneurosci.org/content/34/39/13096.long
Acute administration of Δ9 tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945413/
Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia (full–2014) http://ijnp.oxfordjournals.org/content/ijnp/18/2/pyu018.full.pdf
Genetic predisposition to schizophrenia associated with increased use of cannabis (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382963/
Paranoid Personality Disorder in the United States: The Role of Race, Illicit Drug Use, and Income (full–2014) http://www.tandfonline.com/doi/full/10.1080/15332640.2013.850463
Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332795/
Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations (full–2014) (Warning–graphic photos!) http://www.healio.com/orthopedics/journals/ortho/2014-4-37-4/%7Be1c1de76-8467-4810-8e5f-8f18bde50169%7D/smoking-synthetic-marijuana-leads-to-self-mutilation-requiring-bilateral-amputations
Risk-taking in schizophrenia and controls with and without cannabis dependence (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308438/
Hippocampal Cannabinoid Transmission Modulates Dopamine Neuron Activity: Impact on Rewarding Memory Formation and Social Interaction (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25510937
Cannabis use and suicidal ideations in high-school students (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25123343
Cannabis Use and its Effects on Health, Education and Labor Market Success (link to PDF-2014) http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2414469
Cannabinoids and schizophrenia: therapeutic prospects (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/23829368
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24747871
Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24853061
Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25014618
Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25138234
Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: A brain stimulation reward study (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25092427
Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25392292
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydro-cannabinol (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25454117
top
Developmentally vitamin D-deficient rats show enhanced prepulse inhibition after acute Δ9-tetrahydrocannabinol (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24776491
Impact of Cannabis Use on the Development of Psychotic Disorders (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352721/
Synthetic cannabis-induced mania (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369931/
Cannabidiol Attenuates Sensorimotor Gating Disruption and Molecular Changes Induced by Chronic Antagonism of NMDA receptors in Mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25618402
Cannabidiol Attenuates Sensorimotor Gating Disruption and Molecular Changes Induced by Chronic Antagonism of NMDA receptors in Mice (full–2015) http://ijnp.oxfordjournals.org/content/18/5/pyu041.long
Cannabis and psychopathology: The meandering journey of the last decade (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462782/
Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640353/
A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676097/
Chronic Adolescent Marijuana Use as a Risk Factor for Physical and Mental Health Problems in Young Adult Men (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26237286
Cannabinoids for Medical Use A Systematic Review and Meta-analysis (full–2015) http://jama.jamanetwork.com/article.aspx?articleid=2338251&resultClick=24
Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640936/
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia (full–2015) http://neuro.psychiatryonline.org/doi/full/10.1176/appi.neuropsych.12120398
Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25801289
Further human evidence for striatal dopamine release induced by administration of Δ9- tetrahydrocannabinol (THC): selectivity to limbic striatum (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816196/
Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25572323
Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537180/
Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604232/
The phytocannabinoid, Δ(9) -tetrahydrocannabivarin, can act through 5-HT1 A receptors to produce antipsychotic effects (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337703/
The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects (full–2015) http://journals.sagepub.com/doi/full/10.1177/0269881114565142
Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences (full–2015) http://journals.sagepub.com/doi/full/10.1177/0269881115609073
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling (abst–2015) http://www.cell.com/cell/abstract/S0092-8674%2815%2900826-0?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867415008260%3Fshowall%3Dtrue
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling (full–2015) http://www.cell.com/cell/fulltext/S0092-8674(15)00826-0
Cannabis conundrum : Evidence of harm? : Opposition to marijuana use is often rooted in arguments about the drug’s harm to children and adults, but the scientific evidence is seldom clear-cut (article–2015) http://onlinelibrary.wiley.com/doi/10.1002/cncy.21516/full
Marijuana, Reconsidered: Dr. Lester Grinspoon On 45 Years Of Cannabis Science (interview-2015) http://www.mintpressnews.com/MyMPN/marijuana-reconsidered-an-interview-with-doctor-lestergrinspoon/
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25680767
A systematic review of the antipsychotic properties of cannabidiol in humans (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25667194
For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders (abst–2015) http://www.sciencedirect.com/science/article/pii/S027858461500055X
Association of single nucleotide polymorphisms in catechol-O-methyltransferase and serine-threonine protein kinase genes in the Pakistani schizophrenic population: a study with special emphasis on cannabis and smokeless tobacco (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25801838
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25943166
Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26071625
Catatonia and Cannabis Withdrawal: a case report (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26247767
No additive effect of cannabis on cognition in schizophrenia (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26235754
Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26370602
Endocannabinoids and Mental Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408164
Reduced Brain Cannabinoid Receptor Availability In Schizophrenia (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26432420
The CCDC55 couples cannabinoid receptor CNR1 to a putative DISC1 schizophrenia pathway (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26475744
Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis (abst–2015) http://www.psy-journal.com/article/S0165-1781%2815%2930166-9/abstract
Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26663094
Cannabinoid Transmission in the Hippocampus Activates Nucleus Accumbens Neurons and Modulates Reward and Aversion-Related Emotional Salience (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26681496
An Introduction to the Endogenous Cannabinoid System (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26698193
Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26706691
Cannabidiol and sodium nitroprusside: two novel neuromodulatory pharmacological interventions to treat and prevent psychosis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26350340
top
CB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory (full–2016) http://www.hindawi.com/journals/np/2016/9817089/
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26768595
AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers (full–2016) http://www.nature.com/tp/journal/v6/n2/full/tp2015219a.html
A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder (full–2016) http://link.springer.com/article/10.1007/s11126-016-9426-2/fulltext.html
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (full–2016) https://peerj.com/articles/2081/
Synthetic Cannabinoid Receptor Agonist-Associated Psychotic Disorder: A Case Report (full-2016) http://www.turkpsikiyatri.com/en/default.aspx?modul=article&id=1020
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction (full–2016) http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path %5B%5D=10095&path%5B%5D=31745
First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone (full–2016) http://www.hindawi.com/journals/crips/2016/7257489/
Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158779
Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial (full–2016) http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1507-x
Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History (full–2016) http://journals.plos.org/plosone/article? id=10.1371/journal.pone.0160949
Endocannabinoid signaling in social functioning: an RDoC perspective (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00303/full
Synthetic Cannabis Overdose and Withdrawal in a Young Adult: A Case Report, Commentary on Regulation, and Review of the Literature (full–2016) https://www.hindawi.com/journals/crips/2016/3640549/
Assessing causality in associations between cannabis use and schizophrenia risk: a twosample Mendelian randomization study (full–2016) https://www.cambridge.org/core/journals/psychological-medicine/article/div-classtitleassessing-causalityin-associations-between-cannabis-use-and-schizophrenia-risk-a-two-sample-mendelian-randomizationstudydiv/122D651C3670683DAEDDA33997417105/core-reader
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032490/
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854973/
Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis (full–2016) http://journals.sagepub.com/doi/full/10.1177/0269881116658990
Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients (full–2016) https://www.dovepress.com/clinical-characteristics-of-synthetic-cannabinoid-induced-psychosis-in-peerreviewed-fulltext-article-NDT
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release (full–2016) http://www.cell.com/neuron/fulltext/S0896-6273(16)30509-8
Salience attribution and its relationship to cannabis-induced psychotic symptoms (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122315/
Violence and self-harm in severe mental illness: inpatient study of associations with ethnicity, cannabis and alcohol (full–2016) http://journals.sagepub.com/doi/full/10.1177/1039856216671650
Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit (click “Full Text Links” for PDF–2016) http://www.ncbi.nlm.nih.gov/pubmed/26875559
Suppressing Schizophrenia Symptoms Without Side Effects: Mouse Study (news & abst–2016) http://neurosciencenews.com/schizophrenia-compound-striatum-5089/
Lipids in psychiatric disorders and preventive medicine (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763415303353
Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26783729
Cannabis and Psychosis: a Critical Overview of the Relationship (abst–2016) http://link.springer.com/article/10.1007/s11920-015-0657-y
The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders (abst–2016) http://link.springer.com/article/10.1007/s00213-015-4188-3
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia (abst–2016) http://link.springer.com/article/10.1007/s12035-016-9697-5
A Case of Butane Hash Oil (Marijuana Wax)-Induced Psychosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26820171
Cannabinoids for the Treatment of Schizophrenia: An Overview (abst–2016) http://www.eurekaselect.com/139245/article
Cannabis-induced psychosis associated with high potency “wax dabs” (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26876313
Cannabidiol, neuroprotection and neuropsychiatric disorders (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816000396
Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26970364 Metabolic syndrome in people with a psychotic illness: is cannabis protective? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26965714
Effects of the antipsychotic paliperidone on stress-induced changes in the endocannabinoid system in rat prefrontal cortex (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26987678
Gender Differences in Associations Between Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26903256
Acute Psychosis after Consumption of Synthetic Cannabinoids (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27029042
Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27033329
Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597 (abst–2016) http://www.sciencedirect.com/science/article/pii/S0168010216300220
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27149691
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763415302943
Positron Emission Tomography Studies on Cannabinoid Receptor Type 1 in Schizophrenia (abst–2016) http://www.biologicalpsychiatryjournal.com/article/S0006-3223%2816%2932303-4/abstract
Could cannabidiol be used as an alternative to antipsychotics? (abst–2016) http://www.journalofpsychiatricresearch.com/article/S0022-3956(16)30104-2/abstract
Cannabis and Alcohol Use, Affect, and Impulsivity in Psychiatric Outpatients’ Daily Lives (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27270874
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia (abst 016) http://www.schres-journal.com/article/S0920-9964(16)30060-3/abstract
Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27379411
Does cannabidiol have a role in the treatment of schizophrenia? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27374322
Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatment (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27475408
Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0278584616301269
Cannabis and a lower BMI in psychosis: What is the role of AKT1? (abst–2016) http://www.schres-journal.com/article/S0920-9964(16)30364-4/abstract
Cannabinoids and Psychosis (3) (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27568729
Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27591408
Abnormal white matter integrity in synthetic cannabinoid users (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27617779
Seeing through the smoke: human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763415303638
Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0304394016306930
Cannabinoids: Glutamatergic Transmission and Kynurenines (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27651254
Drug Dependence and Toxicity of Law-Evading Drugs: Their Mechanisms Explored from Basic Research (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27703102
The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27710762
Association of Anandamide with altered Binocular Depth Inversion Illusion in Schizophrenia (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27734750
Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0304394016306930
Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27797288
Pros and cons of medical cannabis use by people with chronic brain disorders (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27804883
Targeting the Endocannabinoid System in Psychiatric Illness (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27811555
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence (abst–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00422/full
The effects of cannabis use on salience attribution: a systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27866486
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763416304390
The consequences of chronic cannabis smoking in vulnerable adolescents (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27986504
Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/28011441
Motivational changes of cannabis use prior to and during the course of schizophrenia (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/28004866
Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27964871
The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data (full–2017) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516- 44462017005002102&lng=en&nrm=iso&tlng=en
The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice (full–2017) http://link.springer.com/article/10.1007%2Fs12640-017-9702-4
Short communication: Genetic association between schizophrenia and cannabis use (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28086176
A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28108228
Cannabis use, COMT, BDNF and age at first-episode psychosis (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28142064


SCLERODERMA
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893662/
Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis (full–2010) http://onlinelibrary.wiley.com/doi/10.1002/art.27642/full
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21177293
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22492781
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22033526
Pathogenesis of Systemic Sclerosis (full–2015) http://journal.frontiersin.org/article/10.3389/fimmu.2015.00272/full
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757881/
Can Cannabinoids Modulate Fibrotic Progression in Systemic Sclerosis? (link to PDF–2016) http://www.ima.org.il/imaj/ViewArticle.aspx?aId=3850
Cannabinoids and autoimmune diseases: A systematic review (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26876387
Cannabinoids, inflammation, and fibrosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27435265
top


SEBACEOUS GLANDS
“Sebocytes’ makeup”: novel mechanisms and concepts in the physiology of the human sebaceous glands (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21384129
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24915599
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (full–2014) http://www.jci.org/articles/view/64628
The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26142529
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrheic skin and acne treatment (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27094344
Targeting Cutaneous Cannabinoid Signaling in Inflammation – A “High”-way to Heal? (full–2017) http://www.ebiomedicine.com/article/S2352-3964(17)30003-8/fulltext


SEBORRHEA
Targeting Cutaneous Cannabinoid Signaling in Inflammation – A “High”-way to Heal? (full–2017) http://www.ebiomedicine.com/article/S2352-3964(17)30003-8/fulltext


SEPTIC SHOCK/SEPSIS
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005548/?tool=pubmed
Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20561509
Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034694/?tool=pmcentrez
The endocannabinoid system in sepsis – a potential target to improve microcirculation? (full–2011) http://www.signavitae.com/articles/review-articles/161-the-endocannabinoid-system-in-sepsis-a-potential-target-to-improve-microcirculation
Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21279327
Cannabinoids and sepsis (abst–2011) http://www.trendsanaesthesiacriticalcare.com/article/S2210-8440%2811%2900049-9/fulltext
Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory mediator release in acute experimental sepsis (full–2012) http://ccforum.com/content/16/2/R47
Cannabinoid receptor 1 inhibition causes seizures during anesthesia induction in experimental sepsis (full–2012) http://journals.lww.com/anesthesia
analgesia/Fulltext/2012/06000/Cannabinoid_Receptor_1_Inhibition_Causes_Seizures.12.aspx
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities (full–2012)
http://rstb.royalsocietypublishing.org/content/367/1607/3353.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
Cannabinoid Receptor 2 Protects against Acute Experimental Sepsis in Mice (full–2013) http://www.hindawi.com/journals/mi/2013/741303/
Cytokine release in sepsis (full–2013) http://file.scirp.org/Html/36257.html
Targeting the Endocannabinoid System to Treat Sepsis (review–2013) http://www.signavitae.com/articles/review-articles/222-targeting-the-endocannabinoid-system-to-treat-sepsis
Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23382309
Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis (full–2014) http://www.hindawi.com/journals/mi/2014/978678/
top
Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080545/
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24644287
Novel approaches to the development of anti-sepsis drugs (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24697209
New horizons for newborn brain protection: enhancing endogenous neuroprotection (full–2015) http://fn.bmj.com/content/early/2015/06/10/archdischild-2014-306284.long
Δ9 Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25425209
Cannabinoid 2 receptor activation reduces leukocyte adhesion and improves capillary perfusionin the iridial microvasculature during systemic inflammation (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26410875
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00264/full Involvement of Central Endothelin ETA and Cannabinoid CB1 Receptors and Arginine Vasopressin Release in Sepsis Induced by Cecal Ligation and Puncture in Rats (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26925810
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763416304390


SICKLE CELL DISEASE
New Era Dawns on Sickle Cell Pain (full–2010) http://bloodjournal.hematologylibrary.org/cgi/reprint/116/3/311
Pain related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids (full–2010) http://bloodjournal.hematologylibrary.org/content/116/3/456.long
Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779783/
Traditional Herbal Management of Sickle Cell Anemia: Lessons from Nigeria (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502758/
Priapism in a patient with sickle cell trait using marijuana (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24798364
Cannabinoid receptor-specific mechanisms to ameliorate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation (link to PDF–2015) http://www.haematologica.org/content/early/2015/12/21/haematol.2015.136523.long
Quantification of pain in sickle mice using facial expressions and body measurements (abst–2016) http://www.sciencedirect.com/science/article/pii/S1079979615300218
Sickle Cell Crisis Complicated by Synthetic Cannabinoid Abuse: A Case Report (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26956672


SLEEP APNEA
Circulating endocannainoids and N-acyl-ethanolamides in patients with sleep apnea – specific role of oleoylethanolamide (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20429051
A study on the endogenous cannabinoid system synthetic and catabolic enzyme levels in patients with obstructive sleep apnea (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21729625
Circulating anandamide and blood pressure in patients with obstructive sleep apnea (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23032139
Proof of concept trial of dronabinol in obstructive sleep apnea (full–2013) http://www.frontiersin.org/Sleep_Disorders/10.3389/fpsyt.2013.00001/full
Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24121138
top
Identification of a Pharmacological Target for Genioglossus Reactivation throughout Sleep (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902869/
Impact of dronabinol on quantitative electroencephalogram (qEEG) measures of sleep in obstructive sleep apnea syndrome (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869068/
Cannabinoid Type 1 and Type 2 Receptor Antagonists Prevent Attenuation of Serotonin Induced Reflex Apneas by Dronabinol in Sprague-Dawley Rats (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0111412
Cannabinoid Type 1 Receptor Antagonist, AM251, Prevents Attenuation Of Serotonin induced Apneas By Dronabinol In Sprague-Dawley Rats (abst–2014) http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A3901
Emerging Drugs for Common Conditions of Sleepiness: Obstructive Sleep Apnea and Narcolepsy (full–2015) http://www.tandfonline.com/doi/full/10.1517/14728214.2015.1115480
Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea (full–2016) http://www.hindawi.com/journals/bmri/2016/9782031/
Intracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley rats (full–2016) http://jnrbm.biomedcentral.com/articles/10.1186/s12952-016-0052-1


SLEEPING SICKNESS / TRYPANOSOMIASIS
Trypanocidal Effect of Cannabis sativa on Experimental Camel Trypansomosis (full–2012) http://scialert.net/fulltext/?doi=rjmp.2012.281.285&org=10


SLEEP MODULATION
Mixed mood disorder (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/228/?pagenum=2
Marijuana helps narcolepsy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/598/?pagenum=2
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950205/?tool=pmcentrez
The Maternal Lifestyle Study: Sleep Problems in Children with Prenatal Substance Exposure (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917192/?tool=pubmed
The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial (full-2010) http://journals.lww.com/anesthesiaanalgesia/Fulltext/2010/02000/The_Effects_of_Nabilone_on_Sleep_in_Fibromyalgia_.56.aspx
Endocannabinoid signalling: has it got rhythm? (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931554/
Sleep and Medicinal Cannabis (abst-2010) http://www.cmcr.ucsd.edu/index.php?option=com_content&view=article&id=151:sleep-and-medicinalcannabis&catid=41:research-studies&Itemid=135
Oleoylethanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20100574
Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20056119
Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136458/?tool=pubmed
A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats (full–2011) http://www.hindawi.com/journals/sd/2011/178469/
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial (full–2011) http://annonc.oxfordjournals.org/content/22/9/2086.long
top
Characterizing smoking topography of cannabis in heavy users (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641906/
Role of Cannabinoids in Multiple Sclerosis (link to PDF-2011) http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.659.8269&rank=26
Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21867717
Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21262236
The emerging role of the endocannabinoid system in the sleep-wake cycle modulation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21919868
CADTH Rapid Response Report: Cannabinoids for the treatment of post-traumatic stress disorder (full–2012) http://www.cadth.ca/media/pdf/htis/july-2012/RC0368%20Cannabinoids%20Final.pdf
Cannabidiol in humans-the quest for therapeutic targets (full–2012) http://www.ncbi.nlm.nih.gov/pubmed/24281562
Neuromodulators for pain management in rheumatoid arthritis (abst–2012) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008921.pub2/abstract
Oleamide restores sleep in adult rats that were subjected to maternal separation (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22975223
A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Flexible Dose, Efficacy Study of Nabilone as Adjuvant in the Treatment of Diabetic Peripheral
Neuropathic Pain Using an Enriched Enrollment Randomized Withdrawal Design (S38.003) (abst–2012) http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/S38.003?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=180&sortspec=date&resourcetype=HWCIT
Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929256/
Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537525/
Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23343597
Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23584096
2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23603032
Cardiorespiratory control as a function of wake-sleep behavior and diet in mice lacking CB1 cannabinoid receptors (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/926.1?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23238438
Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23721537
The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt (abst–2013) http://www.sciencedirect.com/science/article/pii/S030646031300172X
Poor sleep quality as a risk factor for lapse following a cannabis quit attempt (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23098380
Endocannabinoid Modulation of Cortical Up-States and NREM Sleep (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919802/
top
Multiple sleep alterations in mice lacking cannabinoid type 1 receptors (full-2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0089432
Impact of dronabinol on quantitative electroencephalogram (qEEG) measures of sleep in obstructive sleep apnea syndrome (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869068/
Cardiorespiratory Anomalies in Mice Lacking CB1 Cannabinoid Receptors (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0100536
Therapeutic benefits of cannabis: a patient survey (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/
Therapeutic Potential of Cannabinoids in Counteracting Chemotherapy-induced Adverse Effects: An Exploratory Review (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/ptr.5265/full
Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder-Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications: A Retrospective Evaluation (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165471/
Potential effects of cannabidiol as a wake-promoting agent (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023456/
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24420962
Therapeutic Potential of Cannabinoids in Counteracting Chemotherapy-induced Adverse Effects: An Exploratory Review (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25504799
Anandamide activation of CB1 receptors increases spontaneous bursting and oscillatory activity in the thalamus (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24508153
Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24800644
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24845114
Inhibition of diacylglycerol lipase (DAGL) in the lateral hypothalamus of rats prevents the increase in REMS and food ingestion induced by PAR1 stimulation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24996194
Endocannabinoid signaling modulates neurons of the pedunculopontine nucleus (PPN) via astrocytes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25009314
When time stands still: an integrative review on the role of chronodisruption in posttraumatic stress disorder (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25023884
Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25191852
2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25356522
INVESTIGATING SEDATIVE, PREANAESTHETIC & ANTI-ANXIETY EFFECTS OF HERBAL EXTRACT OF CANNABIS SATIVA IN COMPARISON WITH DIAZEPAM IN RATS (abst–2014) http://en.journals.sid.ir/ViewPaper.aspx?ID=354909
Cannabis Withdrawal Among Detained Adolescents: Exploring the Impact of Nicotine and Race (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331066/
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25467221
top
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study (full–2015) http://www.psyneuen-journal.com/article/S0306-4530%2814%2900413-2/fulltext
Cannabis and Cannabinoids–for health professionals (PDQ®) (full–2015) http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/all
Cannabis and Cannabinoids (PDQ®): Patient Version (full–2015) http://www.ncbi.nlm.nih.gov/books/NBK65875/
Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup (full–2015) http://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201504 -195AR#.Vo20QFJwtSE
Cannabinoids for Medical Use A Systematic Review and Meta-analysis (full–2015) http://jama.jamanetwork.com/article.aspx?articleid=2338251&resultClick=24
Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-arachidonoylglycerol (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26612385
Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-arachidonoylglycerol (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763355/
The effects of chronic marijuana use on circadian entrainment (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25801606
Cannabis withdrawal and sleep: A systematic review of human studies (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25893849
Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25935511
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials (full–2015) http://tinyurl.com/ojn89dh
Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26151582
Retrospective Analysis of Tetrahydrocannabinol Based on 31 Neurologically Critically Ill Children (abst–2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1550707
Use and effects of cannabinoids in military veterans with posttraumatic stress disorder (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26195653
Rhythmic control of endocannabinoids in the rat pineal gland (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26061461
Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26151582
Endocannabinoid Signaling Regulates Sleep Stability (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152473
Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans (full–2016) http://www.psyneuen-journal.com/article/S0306-4530(16)30715-6/fulltext
The impact of drugs for multiple sclerosis on sleep (full–2016) http://journals.sagepub.com/doi/full/10.1177/1352458516664034
Cannabis and Cannabinoids (PDQ®)Health Professional Version (full–2016) https://www.ncbi.nlm.nih.gov/books/NBK65755/
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy (full–2016) https://www.hindawi.com/journals/pd/2016/1279042/
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26757043
Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27074158
Direct presynaptic and indirect astrocyte-mediated mechanisms both contribute to endocannabinoid signaling in the pedunculopontine nucleus of mice (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27169390
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27160412
Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatment (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27475408
Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27551883
Marijuana use in adults admitted to a Canadian epilepsy monitoring unit (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27568641
Contribution of health motive to cannabis use among high-school students (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27543835
Disturbances of sleep and circadian rhythms: novel risk factors for obesity (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27584008
Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and Maintenance of Wakefulness Test (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27655451
The hazards of bad sleep-Sleep duration and quality as predictors of adolescent alcohol and cannabis use (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27659736
Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27746343
Endocannabinoids and sleep (abst-2016) http://www.sciencedirect.com/science/article/pii/S0149763416302640
Regulation of fear extinction by long-term depression: the roles of endocannabinoids and brain derived neurotrophic factor (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27867101
Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27919478


SMALLPOX
Cannabinoids lead to enhanced virulence of the smallpox vaccine (vaccinia) virus (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21131094/abstract/Cannabinoids_lead_to_enhanced_virulence_of_the_smallpox_vaccine__vaccinia__virus_
Genome-wide association study of antibody response to smallpox vaccine (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367131/
Possible Immunosuppressive Effects of Drug Exposure and Environmental and Nutritional Effects on Infection and Vaccination (full–2015) http://www.hindawi.com/journals/mi/2015/349176/
top


SMELL/ODOR DETECTION
The endocannabinoid 2-arachidonoyl-glycerol controls odor sensitivity in larvae of Xenopus laevis (full–2010) http://www.jneurosci.org/content/30/26/8965.long
Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: strain differences in drug-induced anxiety (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20875432
Endocannabinoid modulation in the olfactory epithelium (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20865377
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial (full–2011) http://annonc.oxfordjournals.org/content/early/2011/02/11/annonc.mdq727.full
Acute Immobilization Stress Modulate GABA Release from Rat Olfactory Bulb: Involvement of Endocannabinoids-Cannabinoids and Acute Stress Modulate GABA Release (full–2011) http://www.hindawi.com/journals/ijcb/2011/529851/
Cannabinoid receptor-mediated regulation of neuronal activity in the main olfactory bulb (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397690/
Handler beliefs affect scent detection dog outcomes (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078300/
Cannabinoid receptor-mediated regulation of neuronal activity and signaling in glomeruli of the main olfactory bulb (full– 2012) http://www.jneurosci.org/content/32/25/8475.long
G-Protein-Coupled Receptors in Intestinal Chemosensation (full–2012) http://www.sciencedirect.com/science/article/pii/S1550413112000198
Sniffing out pharmacology: interactions of drugs with human olfaction (abst–2012) http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147%2812%2900016-8?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614712000168%3Fshowall%3Dtrue
Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23453134
Identification of odorant-receptor interactions by global mapping of the human odorome (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0093037
Effects of 20 mg oral Δ9 -tetrahydrocannabinol on the olfactory function of healthy volunteers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24802974
Detecting Cannabis Use on the Human Skin Surface via an Electronic Nose System (link to PDF–2014) http://www.mdpi.com/1424-8220/14/7/13256
The endocannabinoid system controls food intake via olfactory processes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24509429
New insights on food intake control by olfactory processes: the emerging role of the endocannabinoid system (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25261796
Cellular Mechanisms of Action of Drug Abuse on Olfactory Neurons (full–2015) http://www.mdpi.com/1660-4601/13/1/5/htm
An endocannabinoid system is present in the mouse olfactory epithelium but does not modulate olfaction (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26037800
A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26162535
A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148734
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016182a.html
Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit. (click “Full Text Links” for PDF–2016) http://www.ncbi.nlm.nih.gov/pubmed/26875559
Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26996621
Effects of analgesics on olfactory function and the perception of intranasal trigeminal stimuli (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27320501
Cannabinoid receptor signaling induces proliferation but not neurogenesis in the mouse olfactory epithelium (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27606334
top


SMOKED CANNABIS AS A MEDICATION
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950205/?tool=pmcentrez
Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study (full–2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325767/
Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma (article-2010) http://www.canadianjournalofophthalmology.ca/article/S0008-4182%2810%2980129-2/abstract
The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program (abst–2010) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=309
Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis inhalation (full–2011) http://cannabisclinicians.org/wp-content/uploads/2011/12/Cannabis-Inhalation-and-Brain-TumorRegression-2011.pdf
Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080871/?tool=pubmed
Posttraumatic Stress and Marijuana Use Coping Motives: The Mediating Role of Distress Tolerance (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101637/
Medical cannabis use in post-traumatic stress disorder: a naturalistic observational study (abst–2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=481
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial (full–2012) http://www.cmaj.ca/content/184/10/1143.long
Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia (full–2012) http://onlinelibrary.wiley.com/doi/10.1002/acr.21732/full
Use of cannabis among 139 cluster headache sufferers (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23197349
Role of Cannabinoids in Multiple Sclerosis (link to PDF-2011) http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.659.8269&rank=26
Seizure exacerbation in two patients with focal epilepsy following marijuana cessation (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23159379
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/25876933
The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (full–2013) http://www.amjmed.com/article/S0002-9343%2813%2900200-3/fulltext
Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV-Hepatitis C Coinfection: A Longitudinal Cohort Analysis (full–2013) http://cid.oxfordjournals.org/content/early/2013/07/03/cid.cit378.long
Towards a better Cannabis drug (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/bph.12400/full
Cannabis and other illicit drug use in epilepsy patients (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/ene.12081/full
The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005175.pub3/full
Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584982/
Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120 (full–2013) http://www.jleukbio.org/content/92/5/1093.full
top
Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study (full–2013) http://www.cghjournal.org/article/S1542-3565%2813%2900604-6/fulltext
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana In Daily Marijuana Smokers (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746706/
Medical Marijuana Coverage Still Lost in the Legal Weeds (article–2013) http://www.managedcaremag.com/linkout/2013/1/23
Medicinal Cannabis and Painful Sensory Neuropathy (editorial–2013) http://virtualmentor.ama-assn.org/2013/05/oped1-1305.html
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24289844
Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23291209
Prescribing smoked cannabis for chronic noncancer pain: Preliminary recommendations (full–2014) http://www.cfp.ca/content/60/12/1083.long
Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0108282
Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950986/
Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170074/
Cannabis smoking and serum C-reactive protein: A quantile regressions approach based on NHANES 2005–2010 (abst–2014) http://www.drugandalcoholdependence.com/article/S0376-8716%2814%2901929-2/abstract?cc=y
Inhaled medicinal cannabis and the immunocompromised patient (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25216851
Inhaled medicinal cannabis and the immunocompromised patient (full – 2014) MASSC
How Smoking Marijuana Might Be The Best Way To Prevent Alzheimer’s Disease (interview–2014) http://www.leafscience.com/2014/01/30/smoking-marijuana-might-best-way-prevent-alzheimers-disease/
Cannabis (Medical Marijuana) Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: An Open-Label Observational Study (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24614667
Marijuana, expectancies, and post-traumatic stress symptoms: a preliminary investigation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25052875
Effect of Marijuana Use on Outcomes in Traumatic Brain Injury (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25264643
Cannabis, cannabidiol, and epilepsy – From receptors to clinical response (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25282526
Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study (abst–2014)
http://www.ncbi.nlm.nih.gov/pubmed/25533893
The Association Between Normal Optic Nerve Cupping , Normal Visual Fields and Marijuana Use (abst–2014) http://iovs.arvojournals.org/article.aspx?articleid=2271290&resultClick=1
top
Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311234/
Use of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use (full–2015) http://ssw.umich.edu/sites/default/files/documents/news/use-of-prescription-pain-medications-amongmedical-cannabis-patients.pdf
Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541447/
Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH) (full–2015) http://cid.oxfordjournals.org/content/61/1/40.long
Life Threatening Idiopathic Recurrent Angioedema Responding to Cannabis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519555/
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders (full–2015) http://ascpjournal.biomedcentral.com/articles/10.1186/s13722-015-0032-7
Self-medication of achalasia with cannabis, complicated by a cannabis use disorder (full–2015) http://www.wjgnet.com/1007-9327/full/v21/i20/6381.htm
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia (full–2015) http://neuro.psychiatryonline.org/doi/full/10.1176/appi.neuropsych.12120398
Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience (abst–2015) http://www.sciencedirect.com/science/article/pii/S0885392414003121
Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25978795
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26152606
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26187456
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data (abst–2015) http://www.jpain.org/article/S1526-5900%2815%2900812-3/abstract
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS) (link to PDF–2015) http://www.jpain.org/article/S1526-5900%2815%2900837-8/abstract
Association Between Cannabis Use and the Risk of Bladder Cancer: Results From the California Men’s Health Study (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25623697
Smoke Your Troubles Away: Exploring the Effects of Death Cognitions on Cannabis Craving and Consumption (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25950588
Combined effects of HIV and marijuana use on neurocognitive functioning and immune status (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26694807
Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26364922
Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26422462
top
Prescribing medical cannabis in Canada: Are we being too cautious? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26451996
Being the Victim of Violence during a Date predicts Next-Day Cannabis Use among Female College Students (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26449928
Is cannabis use associated with less opioid use among people who inject drugs? (abst–2015) http://www.drugandalcoholdependence.com/article/S0376-8716%2815%2900250-1/abstract
Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population (full–2016) http://onlinelibrary.wiley.com/doi/10.1002/phar.1673/full
“I Use Weed for My ADHD”: A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156614
Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157060
Integrating cannabis into clinical cancer care (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791148/
Neuropathic Pain Treatment: Still a Challenge (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935814/
Cannabis and Cannabinoids (PDQ®)Health Professional Version (full–2016) https://www.ncbi.nlm.nih.gov/books/NBK65755/
Marijuana effects on changes in brain structure and cognitive function among HIV+ and HIV- adults (link via ELSEVIER to Full Text–2016) https://www.ncbi.nlm.nih.gov/pubmed/27889592
The use of medical-grade cannabis in patients non-responders to Nabiximols (first page–2016) http://www.jns-journal.com/article/S0022-510X(16)30472-5/abstract
Prior Cannabis Use Is Associated with Outcome after Intracerebral Hemorrhage (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26820826
Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain : A systematic review of randomized controlled studies. (scroll down for English version) (abst–2016) http://link.springer.com/article/10.1007%2Fs00482-015-0089-y
Plant-Derived and Endogenous Cannabinoids in Epilepsy (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26892745
Cannabinoids: Medical implications (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26912385
Cannabis in Pain Treatment: Clinical & Research Considerations (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26961090
Metabolic syndrome in people with a psychotic illness: is cannabis protective? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26965714
The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26889611
No significant effect of cannabis use on the count and percentage of circulating CD4 Tcells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort) (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27073179
Associations of Posttraumatic Stress Disorder Symptoms With Marijuana and Synthetic Cannabis Use Among Young Adult U.S. Veterans: A Pilot Investigation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27172584 Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27267445
Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27551883 Marijuana use in adults admitted to a Canadian epilepsy monitoring unit (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27568641
Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms A Mile High (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27579692
Contribution of health motive to cannabis use among high-school students (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27543835
Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/26809974
Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27723182
Effects of Marijuana on ictal and interictal EEG activity in idiopathic generalized epilepsy (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27763968
Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27842047


SOCIAL ADJUSTMENT/BEHAVIOR
Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996668/?tool=pubmed
Influence of cannabis use trajectories, grade repetition and family background on the school-dropout rate at the age of 17 years in France (full–2010) http://eurpub.oxfordjournals.org/content/20/2/157.long Uni-Morbid and Co-Occurring Uni-Morbid and Co-Occurring Marijuana and Tobacco Use: Examination of Concurrent Associations with Negative Mood States (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861285/?tool=pubmed
Preservation of Striatal Cannabinoid CB1 Receptor Function Correlates with the Antianxiety Effects of Fatty Acid Amide Hydrolase Inhibition (full–2010) http://molpharm.aspetjournals.org/content/78/2/260.long
A Life-course Perspective on the “Gateway Hypothesis” (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20943588
A Sociological Theory of Drug Sales, Gifts, and Frauds (abst–2010) http://cad.sagepub.com/content/60/7/1057.abstract
Patterns of Youth Participation in Cannabis Cultivation (abst–2010) http://jod.sagepub.com/content/40/2/263.abstract
Cannabis and crime: findings from a longitudinal study (abst–2010) http://www.unboundmedicine.com/medline/ebm/record/19839964/full_citation/Cannabis_and_crime:_findings_from_a_longitudinal_study_
Gender moderates the impact of stereotype threat on cognitive function in cannabis users (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20483199
Gender differences in adolescent marijuana use and associated psychosocial characteristics (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359836/
top
Marijuana and Tobacco Use: Examination of Concurrent Associations with Negative Mood States (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861285/?tool=pubmed
Drug-Intake Methods and Social Identity: The Use of Marijuana in Blunts Among Southeast Asian Adolescents and Emerging Adults (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193281/?tool=pubmed
Rural Adolescent Alcohol, Tobacco and Illicit Drug Use: A Comparison of Students in Victoria, Australia and Washington State, United States (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186916/
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/
The social contagion effect of marijuana use among adolescents (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018468/?tool=pubmed
Racial differences in trajectories of heavy drinking and regular marijuana use from ages 13 to 24 among African-American and White males (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258364/
The association between early conduct problems and early marijuana use in college students (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163297/
Profile of Psychoactive Substances Consumption in Workplace (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21635864
Alcohol and cannabis abuse/dependence symptoms and life satisfaction in young adulthood (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21733007
High on Life? Medical Marijuana Laws and Suicide (full–2012) http://ftp.iza.org/dp6280.pdf
Differences in Spontaneously Avoiding or Approaching Mice Reflect Differences in CB1-Mediated Signaling of Dorsal Striatal Transmission (full–2012) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0033260
Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664416/
Cannabidiol in humans-the quest for therapeutic targets (full–2012) http://www.ncbi.nlm.nih.gov/pubmed/24281562
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389197/
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22495620
The combined effects of parental divorce and parental history of depression on cannabis use in young adults in France (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22682099
Cannabis Use Vulnerability Among Socially Anxious Users: Cannabis Craving During a Social Interaction (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23002698
‘It’s just a social thing’: Drug use, friendship and borderwork among marginalized young people (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23352335
Identity Formation, Marijuana and “The Self”: A Study of Cannabis Normalization among University Students (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847659/
top
Fascination and Social Togetherness-Discussions about Spice Smoking on a Swedish Internet Forum (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855086/
Perception of tobacco, cannabis, and alcohol use of others is associated with one’s own use (full–2013) http://www.ascpjournal.org/content/8/1/15
Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584982/
Do societal wealth, family affluence and gender account for trends in adolescent cannabis use? A 30 country cross-national study (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24261614
Do societal wealth, family affluence and gender account for trends in adolescent cannabis use? A 30 country cross-national study (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947129/
Cannabis Use, Employment, and Income: Fixed-Effects Analysis of Panel Data (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867578/
CB1 receptor signaling regulates social anxiety and memory (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/gbb.12045/full
THE IMPORTANCE OF FAMILY RELATIONS FOR CANNABIS USERS: THE CASE OF SERBIAN ADOLESCENTS (full–2013) http://www.sid.ir/en/VEWSSID/J_pdf/86320130302.pdf
Higher rates of adolescent substance use in child welfare versus community populations in the United States (link to PDF-2013) http://www.jsad.com/jsad/article/Higher_Rates_of_Adolescent_Substance_Use_in_Child_Welfare_Versus_Community_/4863.html
Higher rates of adolescent substance use in child welfare versus community populations in the United States (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817044/
The role of child protection in cannabis grow-operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23453301
Can Marijuana Reduce Social Pain? (abst–2013) http://spp.sagepub.com/content/early/2013/05/13/1948550613488949.abstract
From “Social Supply” to “Real Dealing”: Drift, Friendship, and Trust in Drug-Dealing Careers (full–2013) http://jod.sagepub.com/content/43/4/392.full.pdf+html
Identity formation, marijuana and “the self”: a study of cannabis normalization among university students (article–2013) http://journal.frontiersin.org/article/10.3389/fpsyt.2013.00160/full
Creativity in cannabis-users and in drug addicts in maintenance treatment and in rehabilitation (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23359015
Illegal drugs and delinquency (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23434380
Adolescent peer-rejection persistently alters pain perception and CB1 receptor expression in female rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23669059
CB1 cannabinoid receptor-mediated aggressive behavior (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23916480
Cannabis use motives and personality risk factors (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24368004
Cannabis use in a Swiss male prison: Qualitative study exploring detainees’ and staffs’ perspectives (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23773686
The Effect of Medical Marijuana Laws on Crime: Evidence from State Panel Data, 1990-2006 (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0092816
Genetic Variations in the Human Cannabinoid Receptor Gene Are Associated with Happiness (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0093771
Moderate-Vigorous Physical Activity across Body Mass Index in Females: Moderating Effect of Endocannabinoids and Temperament (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125187/
top
An Examination of Opinions Toward Marijuana Policies Among High School Seniors in the United States (full–2014) http://www.tandfonline.com/doi/full/10.1080/02791072.2014.962716#tabModule
Marijuana Policy in Colorado (full–2014) http://object.cato.org/sites/cato.org/files/pubs/pdf/working-paper-24_2.pdf
Early onset of cannabis use: Does personality modify the relation with changes in perceived parental involvement? (full–2014) http://www.drugandalcoholdependence.com/article/S0376-8716%2814%2901893-6/fulltext
Acute alcohol use temporally increases the odds of male perpetrated dating violence: A 90-day diary analysis (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858531/
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users (full 014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398332/
Prevalence and correlates of alcohol and cannabis use disorders in the United States: Results from the national longitudinal study of adolescent health (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963405/
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation (full–2014) http://www.nature.com/tp/journal/v4/n7/full/tp201453a.html
Couples’ Marijuana Use Is Inversely Related to Their Intimate Partner Violence Over the First 9 Years of Marriage (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25134048
Systemic Administration of Oleoylethanolamide Protects from Neuroinflammation and Anhedonia Induced by LPS in Rats (full–2014) http://ijnp.oxfordjournals.org/content/18/6/pyu111
Cannabinoid Modulation of Amygdala Subregion Functional Connectivity to Social Signals of Threat (full-2014) http://ijnp.oxfordjournals.org/content/18/3/pyu104.long
Risk-taking in schizophrenia and controls with and without cannabis dependence (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25467541
Risk-taking in schizophrenia and controls with and without cannabis dependence (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308438/
Hippocampal Cannabinoid Transmission Modulates Dopamine Neuron Activity: Impact on Rewarding Memory Formation and Social Interaction (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25510937
Interpersonal Guilt and Substance Use in College Students (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24579980
Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion (full–2014) http://www.nature.com/tp/journal/v4/n9/full/tp201477a.html
Cannabis Use and its Effects on Health, Education and Labor Market Success (link to PDF-2014) http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2414469
Strain and context-dependent effects of the anandamide hydrolysis inhibitor URB597 on social behavior in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24933531
Role of CNR1 polymorphisms in moderating the effects of psychosocial adversity on impulsivity in adolescents (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24980155
Socialization Instances Linked to Cannabis Experimentation Among French Teenagers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25099311
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25454117
Frequent electronic media communication with friends is associated with higher adolescent substance use (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25471077
Involvement of 2-arachidonoylglycerol signaling in social challenge responding of male CD1 mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25547462
top
Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24577515
Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25024347
Effects of mood inductions by meal ambiance and moderate alcohol consumption on endocannabinoids and N-acylethanolamines in humans: a randomized crossover trial (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126421
Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors (full–2015) http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002194
Stigma among California’s Medical Marijuana Patients (full–2015) http://www.ncbi.nlm.nih.gov/pubmed/25715067
To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681836/
The role of the Cannabinoid Receptor 1 in adolescents’ processing of facial expressions (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/ejn.13118/full
Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety like behavior and sociability (full–2015) http://journal.frontiersin.org/article/10.3389/fnbeh.2015.00235/full
Neuropsychological sex differences associated with age of initiated use among young adult cannabis users (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25832823
Neuropsychological sex differences associated with age of initiated use among young adult cannabis users (full-2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441859/
Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains (abst–2015) http://www.sciencedirect.com/science/article/pii/S0376871614020006
Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains (full–2015) http://www.sciencedirect.com/science/article/pii/S0376871614020006
Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25960036
Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes (full–2015) http://www.sciencedirect.com/science/article/pii/S0149763415001244
Reasons for recent marijuana use in relation to use of other illicit drugs among high school seniors in the United States (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26115351
Reasons for recent marijuana use in relation to use of other illicit drugs among high school seniors in the United States (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592162/
Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26468198
Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604232/
Prevalence of Marijuana-Related Traffic on Twitter, 2012-2013: A Content Analysis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491148/
Twitter Chatter about Marijuana (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306811/
Social anxiety and cannabis cravings: The influences of parent injunctive norms and tension reduction expectancies (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646225/
Cannabidiol as a Potential Treatment for Anxiety Disorders (full–2015) http://link.springer.com/article/10.1007/s13311-015-0387-1
Effects of amphetamine, morphine, and CP 55, 940 on Go/No-Go task performance in rhesus monkeys (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497858/
Dissecting the cannabinergic control of behavior: The where matters (abst–2015) http://onlinelibrary.wiley.com/doi/10.1002/bies.201500046/abstract;jsessionid=222EC084D6C5E7ECF95BFF9D2752CFE4.f01t01
Role of CB2 receptors in social and aggressive behavior in male mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25921034
From substance use to homelessness or vice versa? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25989002
Use and effects of cannabinoids in military veterans with post-traumatic stress disorder (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26195653
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26391492
Maternal separation and early stress cause long-lasting effects on dopaminergic and endocannabinergic systems and alters dendritic morphology in the nucleus accumbens and frontal cortex in rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26539755
top
Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26706691
Who receives cannabis use offers: A general population study of adolescents (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26433564
The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26747370
Natural outcome of cannabis use disorder: a 3-year longitudinal follow-up (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26212076
Being the Victim of Violence during a Date predicts Next-Day Cannabis Use among Female College Students (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26449928
Investigating cannabis use normalization by distinguishing between experimental and regular use: a multilevel study in 31 countries (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25785792
Difficulties in emotion regulation are associated with panic symptom severity following a quit attempt among cannabis dependent veterans (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25034429
Dissociating the role of endocannabinoids in the pleasurable and motivational properties of social play behaviour in rats (full–2016) http://www.sciencedirect.com/science/article/pii/S1043661816303917
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction (full–2016) http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path %5B%5D=10095&path%5B%5D=31745
Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803149/
Endocannabinoid signaling in social functioning: an RDoC perspective (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016182a.html
Adverse Social Experiences in Adolescent Rats Result in Enduring Effects on Social Competence, Pain Sensitivity and Endocannabinoid Signaling (full–2016) http://journal.frontiersin.org/article/10.3389/fnbeh.2016.00203/full
Interacting Cannabinoid and Opioid Receptors in the Nucleus Accumbens Core Control Adolescent Social Play (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110529/
Solitary cannabis use frequency mediates the relationship between social anxiety and cannabis use and related problems (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147422/
Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/add.13645/full
Lifelong imbalanced linoleic/alpha-linolenic acid intake impairs emotional and cognitive behavior in adult rats via changes in brain endocannabinoid system (click “Full Text Links” to download–2016) https://www.ncbi.nlm.nih.gov/pubmed/27903595
The Effect of Medical Marijuana on Sickness Absence (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27416978
Lipids in psychiatric disorders and preventive medicine (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763415303353
A Genetic Component to National Differences in Happiness (abst–2016) http://link.springer.com/article/10.1007/s10902-015-9712-y
Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26769333
From “herbal highs” to the “heroin of cannabis”: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum (abst–2016) http://www.sciencedirect.com/science/article/pii/S0955395916000347
Social defeat leads to changes in the endocannabinoid system; an overexpression of calreticulin and motor impairment in mice (abst–2016) http://www.sciencedirect.com/science/article/pii/S0166432816300328
A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26873082
Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597 (abst–2016) http://www.sciencedirect.com/science/article/pii/S0168010216300220
Adolescent social rejection alters pain processing in a CB1 receptor dependent manner. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27157075
Social Anxiety and Cannabis-Related Impairment: The Synergistic Influences of Peer and Parent Descriptive and Injunctive Normative Perceptions (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27144526
Neural endocannabinoid CB1 receptor expression, social status, and behavior in male European starlings (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27206544
Neural mechanisms of sensitivity to peer information in young adult cannabis users (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27068178
Declining Prevalence of Marijuana Use Disorders Among Adolescents in the United States, 2002 to 2013 (abst – 2016) http://www.jaacap.com/article/S0890-8567%2816%2930101-0/abstract
Cannabis and Alcohol Use, Affect, and Impulsivity in Psychiatric Outpatients’ Daily Lives. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27270874
Traffic accidentability and risky driving behavior in young people in New Caledonia. of study (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27259836
Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27453335
The neurobiology of social play and its rewarding value in rats. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0149763416303724 Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S1043661816308660
Risky substance use and peer pressure in Swiss young men: Test of moderation effects. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27632359
Restricted vs. unrestricted wheel running in mice: Effects on brain, behavior and endocannabinoids. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0018506X16301799
UPPS-P model impulsivity and marijuana use behaviors in adolescents: A meta-analysis (abst–2016) http://www.drugandalcoholdependence.com/article/S0376-8716(16)30923-1/abstract
Changing perspectives on marijuana use during early adolescence and young adulthood: Evidence from a panel of cross-sectional surveys. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27750184
The neurobiology of social play and its rewarding value in rats (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0149763416303724
Determining Cannabis Use Status From a Photograph: An Assessment of the “Jay-dar” in Neuropsychologists (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27779445
A social network analysis of substance use among immigrant adolescents in six European cities (abst–2016) http://www.sciencedirect.com/science/article/pii/S027795361630538X
Alcohol, tobacco and cannabis use: Do students with mild-intellectual disability mimic students in the general population? (abst–2016) http://www.sciencedirect.com/science/article/pii/S089142221630230X
Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/28008372
Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA (full–2017) http://journals.sagepub.com/doi/abs/10.1177/0269881116684336?url_ver=Z39.88- 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Modelling possible causality in the associations between unemployment, cannabis use, and alcohol misuse (abst–2017) http://www.sciencedirect.com/science/article/pii/S0277953617300011
Cannabis use and dating violence among college students: A call for research (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28109121
Social factors in marijuana use for medical and recreational purposes (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28132734
Alternate policing strategies: Cost-effectiveness of cautioning for cannabis offences (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28139329


SOCIAL MEDIA/INTERNET
The identification of rimonabant polymorphs, sibutramine and analogues of both in counterfeit Acomplia bought on the internet (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/20828968
Internet Highs-Seizures After Consumption of Synthetic Cannabinoids Purchased Online (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22824736
Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636012/ Fascination and Social Togetherness-Discussions about Spice Smoking on a Swedish Internet Forum (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855086/
UR-144 in products sold via the Internet: Identification of related compounds and characterization of pyrolysis products (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23315949
An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS) (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641512/
Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25191852
Frequent electronic media communication with friends is associated with higher adolescent substance use (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25471077
Prevalence of Marijuana-Related Traffic on Twitter, 2012-2013: A Content Analysis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491148/
Twitter Chatter about Marijuana (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306811/
Cannabis Mobile Apps: A Content Analysis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705020/
Using Web searches to track interest in synthetic cannabinoids (aka ‘herbal incense’) (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412351/
“Time for dabs”: Analyzing Twitter data on marijuana concentrates across the US. (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581982/
Displays of dabbing marijuana extracts on YouTube (abst–2015) http://www.drugandalcoholdependence.com/article/S0376-8716(15)01613-0/abstract
Tracking Dabbing Using Search Query Surveillance: A Case Study in the United States (full–2016) http://www.jmir.org/2016/9/e252/
Ecological Momentary Assessment and Smartphone Application Intervention in Adolescents with Substance Use and Comorbid Severe Psychiatric Disorders: Study Protocol (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028912/
“When ‘Bad’ is ‘Good'”: Identifying Personal Communication and Sentiment in Drug Related Tweets. (full – 2016) http://publichealth.jmir.org/2016/2/e162/
Marijuana: Views on Its Medical Use Recorded at the Slovak Social Network (full–2016) http://journals.sagepub.com/doi/full/10.1177/0047237916646442
“I Use Weed for My ADHD”: A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD (full–2016) http://journals.plos.org/plosone/article? id=10.1371/journal.pone.0156614
From “herbal highs” to the “heroin of cannabis”: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum (abst–2016) http://www.sciencedirect.com/science/article/pii/S0955395916000347 “Those edibles hit hard”: Exploration of Twitter data on cannabis edibles in the US. (abst–2016) http://www.drugandalcoholdependence.com/article/S0376-8716%2816%2930056-4/abstract
Marijuana-Related Posts on Instagram (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27262456
A content analysis of tweets about high-potency marijuana (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27402550
Assessing the Validity of Online Drug Forums as a Source for Estimating Demographic and Temporal Trends in Drug Use (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27466069
Exploring Marijuana Advertising on Weedmaps, a Popular Online Directory (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27534665
Buying drugs on a Darknet market: A better deal? Studying the online illicit drug market through the analysis of digital, physical and chemical data (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27611957
Examination of YouTube videos related to synthetic cannabinoids (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27639268 The Synthetic Cannabinoids Phenomenon (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27655416


SPACEFLIGHT/OUTER SPACE
Effects of parabolic flight and spaceflight on the endocannabinoid system in humans (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23023882
Neurophysiology of space travel: energetic solar particles cause cell type-specific plasticity of neurotransmission (full–2016) http://link.springer.com/article/10.1007%2Fs00429-016-1345-3


SPASTICITY
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835560/?tool=pmcentrez
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis (abst-2010) http://msj.sagepub.com/cgi/content/abstract/16/6/707?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabis&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT
Role of cannabinoids in the treatment of pain and (painful) spasticity (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/21142261
Dronabinol for the treatment of unspecific pain, restlessness and spasticity in neuropaediatrics (abst–2010) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1265622
top
Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids (link to PDF–2011) http://www.dovepress.com/articles.php?article_id=7675
Role of Cannabinoids in Multiple Sclerosis (link to PDF-2011) http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.659.8269&rank=26
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (abst–2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=322
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21456949/abstract/THC_and_CBD_oromucosal_spray__Sativex%C2%AE__in_the_management_of_spasticity_associated_with_multiple_sclerosis_
Cannabinoids in children (abst–2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=295
FROM GHENNAB TO CANNABIS: HOPES TO FIND A CURE FOR MULTIPLE SCLEROSIS ARE FLOURISHING (abst–2011) http://en.journals.sid.ir/ViewPaper.aspx?ID=228000
The Therapeutic Potential of Cannabis and Cannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442177/
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with
symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols) (full–2012) http://msj.sagepub.com/content/18/2/219.long
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423911/pdf/ISRN.NEUROLOGY2012 -802649.pdf
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial (full–2012) http://www.cmaj.ca/content/184/10/1143.long
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437528/
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22509985
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/25876933
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22954177
What place for cannabis extract in MS? (abst–2012) http://dtb.bmj.com/content/50/12/141.abstract
Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23011861
Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23072659
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis (full–2013) http://zl.elsevier.es/en/revista/neurologia-495/articulo/clinical-experiences-with-cannabinoids-in-90328787
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists (full–2013) http://www.fasebj.org/content/28/1/117.long
top
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23369054
Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/22726074
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23369055
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/22878432
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24289844
Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience (full–2014) http://www.karger.com/Article/FullText/357743
THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies (full–2014) http://www.karger.com/Article/FullText/357742
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways (full–2014) http://www.karger.com/Article/Pdf/367615
Complementary and alternative medical therapies in multiple sclerosis-the american academy of neurology guidelines: a commentary (full–2014) http://www.clinicaltherapeutics.com/article/S0149-2918%2814%2900684-5/fulltext
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosisrelated spasticity (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24392812
Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice – Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24525548
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24671907
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24943098
Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25121144
Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25191852
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25331416
There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25350886
“Disease Modifying Nutricals” for multiple sclerosis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25435020
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Cortico-spinal Modulation (full–2015) http://www.hindawi.com/journals/np/2015/656582/
top
Cannabinoids for Medical Use A Systematic Review and Meta-analysis (full–2015) http://jama.jamanetwork.com/article.aspx?articleid=2338251&resultClick=24
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders (full–2015) http://ascpjournal.biomedcentral.com/articles/10.1186/s13722-015-0032-7
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis (full–2015) http://jama.jamanetwork.com/article.aspx?articleid=2338251
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26103031
Medical Marijuana: Is the Cart Before the Horse? (1st page–2015) http://jama.jamanetwork.com/article.aspx?articleid=2338230
A sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25857324
Clinical perspectives on medical marijuana (cannabis) for neurologic disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26336632
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604175/
Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25208898
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25796592
Modulatory effects by CB1 receptors on rat spinal locomotor networks after sustained application of agonists or antagonists (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26126926
Retrospective Analysis of Tetrahydrocannabinol Based on 31 Neurologically Critically Ill Children (abst–2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1550707
Cannabinoids for the Treatment of Movement Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26206230
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis (abst–2015) http://informahealthcare.com/doi/abs/10.1586/14737175.2015.1067607
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26325482
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710104/
top
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms (full–2016) http://www.karger.com/Article/FullText/444235
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain (full–2016) http://www.karger.com/Article/FullText/444234
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity (full–2016) http://jnnp.bmj.com/content/early/2016/05/08/jnnp-2015-312591.long
Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270417/
The use of medical-grade cannabis in patients non-responders to Nabiximols (first page–2016) http://www.jns-journal.com/article/S0022-510X(16)30472-5/abstract
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26750641
Nabilone for the Management of Pain (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26923810
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27003093
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27160412
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis (abst–2016) http://www.msard-journal.com/article/S2211-0348(16)30056-6/abstract
Role of nurses in the managements of symptoms associated with spasticity in patients with multiple sclerosis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27492746 Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27772772
Pros and cons of medical cannabis use by people with chronic brain disorders (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27804883
Medical Marijuana: Just the Beginning of a Long, Strange Trip? (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27660328
Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27919478
Cannabis use in persons with traumatic spinal cord injury in Denmark (link to PDF- 2017) https://www.medicaljournals.se/jrm/content/abstract/10.2340/16501977-2105


SPINAL CORD INJURY
Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826109/?tool=pubmed
R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869361/
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20434606
Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study (abst–2010) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=313
Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20920894
The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20156559
Cannabinoid Agonists Inhibit Neuropathic Pain Induced by Brachial Plexus Avulsion in Mice by Affecting Glial Cells and MAP Kinases (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172222/?tool=pubmed
Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235339/
Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159760/
Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21354467
Targetting CB1 Cannabinoid Receptor for Neuroprotetion in Spinal Cord Injury (abst–2011) http://www.fasebj.org/cgi/content/meeting_abstract/25/1_MeetingAbstracts/lb422?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=80&sortspec=date&resourcetype=HWCIT
Spinal Cord Injuries Induce Changes of CB1 Cannabinoid Receptor and C-C Chemokine Expression in Brain Areas Underlying Circuitry of Chronic Pain Conditions (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21265596/abstract/Spinal_Cord_Injuries_Induce_Changes_of_CB1_Cannabinoid_Receptor_and_C_C_Chemokine_Expression_in_Brain_Areas_Underlying_Circuitry_of_Chronic_Pain_Conditions_
top
Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21915768
Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22210507
EFFECT OF AQUATIC EXTRACT OFCANNABIS SATIVA LEAVES ON DEGENERATION OF ALPHA MOTONEURONS IN SPINAL CORD AFTER SCIATIC NERVE COMPRESSION IN RATS (abst–2011) http://en.journals.sid.ir/ViewPaper.aspx?ID=258699
Early Endogenous Activation of CB1 and CB2 Receptors after Spinal Cord Injury Is a Protective Response Involved in Spontaneous Recovery (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496738/
A Role for the Cannabinoid 1 Receptor in Neuronal Differentiation of Adult Spinal Cord Progenitors in vitro is Revealed through Pharmacological Inhibition and Genetic Deletion (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265030/?tool=pubmed
A cell population that strongly expresses the CB1 cannabinoid receptor in the ependyma of the rat spinal cord (abst–2012) http://www.biomedexperts.com/Abstract.bme/22791629/A_cell_population_that_strongly_expresses_the_CB1_cannabinoid_receptor_in_the_ependyma_of_the_rat_spinal_cord
The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22201038
Specific inhibition of the JNK pathway promotes locomotor recovery and neuro-protection after mouse spinal cord injury (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22426389
Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma (full–2013) http://www.jneuroinflammation.com/content/10/1/20
Neuroprotective effects of Cannabis sativa leaves extracts on α-Motoneurons density after sciatic nerve injury in rats (full–2013) http://www.lifesciencesite.com/lsj/life1005s/113_15973life1005s_644_648.pdf
A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury (full–2013) http://www.jneuroinflammation.com/content/10/1/91
Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury (full–2013) http://www.sciencedirect.com/science/article/pii/S0306452213007835
Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries (link to PDF–2013) http://www.eurekaselect.com/107976/article
Medicinal Cannabis and Painful Sensory Neuropathy (editorial – 2013) http://journalofethics.ama-assn.org/2013/05/oped1-1305.html
Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23813098
Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23981015
Heterogeneous presynaptic distribution of monoacylglycerol lipase, a multipotent regulator of nociceptive circuits in the mouse spinal cord (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979158/
top
Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia (full–2014) http://www.sciencedirect.com/science/article/pii/S0306452213010531
Cannabinoid CB2 receptor (CB2R) stimulation delays rubrospinal mitochondrial dependent degeneration and improves functional recovery after spinal cord hemisection by ERK1/2 inactivation (full–2014) http://www.nature.com/cddis/journal/v5/n9/full/cddis2014364a.html
Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0113161
Effects of repeated dosing with mechanistically distinct antinociceptive ligands in a rat model of neuropathic spinal cord injury pain (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184706/
Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury (full–2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844071/
Report on Medical Cannabis Research, What the Science Says (article–2014) http://www.safeaccessnow.org/medical_cannabis_research_what_does_the_evidence_say
Descending modulation of pain: the GABA disinhibition hypothesis of analgesia (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25064178
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? (full–2015) http://www.jneuroinflammation.com/content/pdf/s12974-014-0216-1.pdf
PROGRESS REPORT Compassionate Use of Medical Cannabis Pilot Program Act July 1, 2014 through June 30, 2015 (full–2015) http://dph.illinois.gov/sites/default/files/publications/publicationohpmmedical-cannabis-annual-report-2015.pdf
Spinal RGS4 inhibition effectively attenuates neuropathic hyperalgesia and restores cannabinoid receptor type 1 signaling (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26478461
Spinal RGS4 inhibition effectively attenuates neuropathic hyperalgesia and restores cannabinoid receptor type 1 signaling (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13324/full
Cannabinoids to treat spinal cord injury (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25805333
CB 1Cannabinoid Receptor Agonist Inhibits Matrix Metalloproteinase Activity in Spinal Cord Injury: A Possible Mechanism of Improved Recovery (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25881484
N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26055231
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00264/full
A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. (link to PDF – 2016) https://www.dovepress.com/a-preliminary-evaluation-of-the-relationship-of-cannabinoid-blood-conc-peerreviewed-article-JPR
Effect of cannabinoids on CGRP release in the isolated rat lumbar spinal cord (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26762784
The molecular mechanism and effect of cannabinoid-2 receptor agonist on the bloodspinal cord barrier permeability induced by ischemia-reperfusion injury (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26835555
An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain from Spinal Cord Injury and Disease (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27286745
A study of cannabinoid-1 receptors during the early phase of excitotoxic damage to rat spinal locomotor networks in vitro (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27450568
Type-2 cannabinoid receptors in neurodegeneration (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816306983
Examining the Relationship Between Traumatic Brain Injury and Substance Use Outcomes in the Canadian Population (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27484302
Activation of cannabinoid CB1 receptor contributes to suppression of spinal nociceptive transmission and inhibition of mechanical hypersensitivity by Aβ-fiber stimulation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27589093
Cannabis use in persons with traumatic spinal cord injury in Denmark (link to PDF- 2017) https://www.medicaljournals.se/jrm/content/abstract/10.2340/16501977-2105 Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28107590


SPINOCEREBELLAR ATAXIA/SCA
Disruption of metabotropic glutamate receptor signalling is a major defect at cerebellar parallel fibre-Purkinje cell synapses in staggerer mutant mice (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145934/
Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/23808969
Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24642775
Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3 (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27717809
top


SPLEEN
Regulatory effect of cannabinoid receptor agonist on chemokine-induced lymphocyte chemotaxis (full–2011) https://www.jstage.jst.go.jp/article/bpb/34/7/34_7_1090/_pdf
Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182059/
Differential Modulation by Delta(9)-Tetrahydrocannabinol (∆ (9)-THC) of CD40 Ligand (CD40L) Expression in Activated Mouse Splenic CD4(+) T cells (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657729/
Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120 (full–2013) http://www.jleukbio.org/content/92/5/1093.full
Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0067587
Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687668/
Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice (full–2013) http://atvb.ahajournals.org/content/33/2/215.long
Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23508466
Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25497453
4′-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation (full–2015) http://www.jneuroinflammation.com/content/pdf/s12974-015-0307-7.pdf
Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363052/
Expression Analysis of CB2-GFP BAC Transgenic Mice (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138986
A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis (full–2015) http://darujps.biomedcentral.com/articles/10.1186/s40199-015-0131-8
Lipopolysaccharide Suppresses Carboxylesterase 2g Activity and 2-Arachidonylglycerol Hydrolysis: A Possible Mechanism to Regulate Inflammation (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26403860
Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26411568
Effects of Adolescent Intermittent Alcohol Exposure on the Expression of Endocannabinoid Signaling-Related Proteins in the Spleen of Young Adult Rats (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035052/
Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27287619


SPORTS
Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20872894
top
High-performance sport, marijuana, and cannabimimetics (full–2011) http://jat.oxfordjournals.org/content/35/9/624.long
Prevalence of Synthetic Cannabinoids in U.S. Athletes: Initial Findings (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22872465
Why should Cannabis be Considered Doping in Sports? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654312/
Hair-based rapid analyses for multiple drugs in forensics and doping: application of dynamic multiple reaction monitoring with LC-MS/MS (full–2014) http://journal.chemistrycentral.com/content/8/1/73
UPLC-ESI-Q-TOF-MSE identification of urinary metabolites of the emerging sport nutrition supplement methoxyisoflavone in human subjects (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24742771
Annual banned-substance review: analytical approaches in human sports drug testing (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/dta.1769/full
Cannabis and Exercise Science: A Commentary on Existing Studies and Suggestions for Future Directions (abst–2015) http://link.springer.com/article/10.1007/s40279-015-0362-3
Prevalence and Correlates of Any and Frequent Synthetic Cannabinoid Use in a Representative Sample of High School Students (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27191966
Synthetic Cannabinoid Use and Descriptive Norms among Collegiate Student-Athletes (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27224428
Prevalence and correlates of cannabis use among athletes-A systematic review (abst–2016) http://onlinelibrary.wiley.com/doi/10.1111/ajad.12425/abstract;jsessionid=3C2708E042EA30F4C17299B0 175A10ED.f01t03


STEM CELLS
Endocannabinoids Are Expressed in Bone Marrow Stromal Niches and Play a Role in Interactions of Hematopoietic Stem and Progenitor Cells with the Bone Marrow Microenvironment (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975171/?tool=pubmed
Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099594/
Pleiotropic effects of prostaglandin E(2) in hematopoiesis; prostaglandin E(2) and other eicosanoids regulate hematopoietic stem and progenitor cell function (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21722751
Endocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development (full–2012) http://rstb.royalsocietypublishing.org/content/367/1607/3229.long
G protein-coupled receptor crosstalk and signaling in hematopoietic stem and progenitor cells (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22901257
Type-1 (CB(1)) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0054271
The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842278/
The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation: implications for bone health (full–2013) http://www.hindawi.com/journals/sci/2013/796715/
The effect cannabichromene on adult neural stem/progenitor cells (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23941747
Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24076098
Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on astrogliogenesis through the endocannabinoid system (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/jnr.23231/abstract
top
Modulation of subventricular zone oligodendrogenesis: a role for hemopressin? (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936357/
Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. (link to PDF–2014) http://life.scichina.com:8082/sciCe/EN/abstract/abstract513395.shtml#
Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells (full–2015) http://www.hindawi.com/journals/bmri/2015/874982/
A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428713/
A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways (full–2015) http://link.springer.com/article/10.1007/s11481-015-9609-x/fulltext.html
Inhibition of FAAH confers increased stem cell migration via PPARα (full-2015) http://www.jlr.org/content/early/2015/08/11/jlr.M061473.long
CB1 cannabinoid receptor enrichment in the ependymal region of the adult human spinal cord (full–2015) http://www.nature.com/articles/srep17745
Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26114153
Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476410/
Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via PGE2 and P-selectin Activity (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25931248
Cannabinoid Receptor‐2 Regulates Embryonic Hematopoietic Stem Cell Development via Prostaglandin E2 and P‐Selectin Activity (abst–2015)
http://www.ingentaconnect.com/search/article?option1=tka&value1=cannabinoid&sortDescending=true&sortField=prism_publicationDate&pageSize=10&index=41
Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2 (full–2016) http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=7042&path%5B%5D=20008
Cannabinoid receptor 2 modulates susceptibility to experimental cerebral malaria through a CCL17-dependent mechanism (full–2016) http://www.jbc.org/content/early/2016/07/29/jbc.M116.746594.long
Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells (full–2016) http://www.mdpi.com/1422-0067/18/1/26
Functional effects of cannabinoids during dopaminergic specification of human neural precursors derived from induced pluripotent stem cells (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27027565
Cannabinoid Receptor 1 Mediates Homing of Bone Marrow-Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27028843
Distinctive effects of eicosapentaenoic and docosahexaenoic acids in regulating neural stem cell fate are mediated via endocannabinoid signalling pathways. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0028390816301277
Regulated endosomal trafficking of Diacylglycerol lipase alpha (DAGLα) generates distinct cellular pools; implications for endocannabinoid signaling (abst–2016) http://www.sciencedirect.com/science/article/pii/S104474311630135X
Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked with Amyotrophic Lateral Sclerosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27714895
Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27778331
Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27918106


STIFF-PERSON SYNDROME/HYPEREKPLEXIA DISEASE
Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/22726074
Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019963/
top


STRAIN INFORMATION
Investigations into the Hypothesis of Transgenic Cannabis (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/22211569
Analysis of Genetic Diversity using SSR Markers and Cannabinoid Contents in Different Varieties of Cannabis sativa L. (abst – 2011) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0031-1273534
CYTOLOGICAL STUDIES OF CANNABIS SATIVA IN SHIMLA HILLS OF HIMACHAL PRADESH (full – 2012) http://www.cibtech.org/J-LIFE-SCIENCES/PUBLICATIONS/2012/Vol%202%20No %201/41%20%20Suman%20Kaushal%20Kangra.pdf
Hemp Biology – Industrial Hemp vs. Marijuana (article – 2012) http://www.innvista.com/health/foods/hemp/hemp-biology/
Cannabis – from cultivar to chemovar (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22362625
Extraction of high quality DNA from seized moroccan cannabis resin (hashish) (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790795/
From 32 ounces to zero: a medical geographic study of dispensing a cultivated batch of “plum” cannabis flowers to medical marijuana patients in Washington State (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23909002
Cold acclimation induces distinctive changes in the chromatin state and transcript levels of COR genes in Cannabis sativa varieties with contrasting cold acclimation capacities (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25534661
Characterisation of cannabinoid composition in a diverse Cannabis sativa L. germplasm collection (link to PDF – 2015) http://link.springer.com/article/10.1007/s10681-015-1585-y
Effect of induced polyploidy on some biochemical parameters in Cannabis sativa L. (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25492688
Size matters: evolution of large drug-secreting resin glands in elite pharmaceutical strains of Cannabis sativa (marijuana) (abst – 2015) http://link.springer.com/article/10.1007/s10722-015-0254-2
Variability in Seed Traits in a Collection of Cannabis sativa L. Genotypes (full – 2016) http://journal.frontiersin.org/article/10.3389/fpls.2016.00688/full
A Belated Green Revolution for Cannabis: Virtual Genetic Resources to Fast-Track Cultivar Development. (full – 2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965456/
Pain, Cannabis Species, and Cannabis Use Disorders. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27172585
In vitro Antimicrobial and Antioxidant Activity of Extracts from Six Chemotypes of Medicinal Cannabis (abst–2016) https://www.thieme-connect.com/DOI/DOI?10.1055/s-0036-1596302


STRESS
Endogenous cannabinoid signaling is essential for stress adaptation (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889099/?tool=pmcentrez
Motion Sickness, Stress and the Endocannabinoid System (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873996/?tool=pmcentrez
Maternal Dietary Fat Determines Metabolic Profile and the Magnitude of Endo-cannabinoid Inhibition of the Stress Response in Neonatal Rat Offspring (full–2010) http://endo.endojournals.org/content/151/4/1685.full?sid=f9729cff-d221-42d4-81d8-8545db5df878
Deficiency in Endocannabinoid Signaling in the Nucleus Accumbens Induced by Chronic Unpredictable Stress (full-2010) http://www.nature.com/npp/journal/v35/n11/full/npp201099a.html
Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242307/
Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236282/
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress (full–2011) http://www.sciencedirect.com/science/article/pii/S0091305711002310
Alterations in Corticolimbic Dendritic Morphology and Emotional Behavior in Cannabinoid CB1 Receptor–Deficient Mice Parallel the Effects of Chronic Stress (full–2011) http://cercor.oxfordjournals.org/content/21/9/2056.full
Endocannabinoids and the cardiovascular response to stress (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21708837
Effects of exercise stress on the endocannabinoid system in humans under field conditions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22101870
Cannabinoid receptor expression and phosphorylation are differentially regulated between male and female cerebellum and brain stem after repeated stress: Implication for PTSD and drug abuse (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21600961
Activation of Type 5 Metabotropic Glutamate Receptors and Diacylglycerol Lipase-α Initiates 2-Arachidonoylglycerol Formation and Endocannabinoid-Mediated Analgesia (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652685/
Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice (full–2012) http://eurheartj.oxfordjournals.org/content/33/24/3124.full
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549323/
Acute Stress Increases Circulating Anandamide and Other N-Acylethanolamines in Healthy Humans (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442338/
Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [11C]-(+)-PHNO (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572464/
Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242307/
Neural Substrates Underlying Interactions between Appetite Stress and Reward (full–2012) https://www.karger.com/Article/FullText/338237
top
The biochemical complexity of the endocannabinoid system with some remarks on stress and related disorders: a minireview (link to PDF–2012) http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=2854&categor
y_id=93&keyword=cannabinoid&option=com_virtuemart&Itemid=1
Cannabinoid modulation of midbrain urocortin 1 neurones during acute and chronic stress (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22734681
Anti-Inflammatory Effect of the Endocannabinoid Anandamide in Experimental Periodontitis and Stress in the Rat (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22777139
Cannabinoid CB(1) receptor in the modulation of stress coping behaviour in mice: the role of serotonin and different forebrain neuronal subpopulations (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23000076
Anti-Inflammatory Effect of the Endocannabinoid Anandamide in Experimental Periodontitis and Stress in the Rat (abst–2012) http://content.karger.com/produktedb/produkte.asp?doi=339113
Age of Stress Exposure Modulates the Immediate and Sustained Effects of Repeated Stress on (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23200786
Ventral Tegmental Area Cannabinoid Type-1 Receptors Control Voluntary Exercise Performance (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23237313
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22979992
Translational evidence for the involvement of the endocannabinoid system in stress related psychiatric illnesses (full–2013) http://www.biolmoodanxietydisord.com/content/3/1/19
Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682147/
Cannabinoid modulation of chronic mild stress-induced selective enhancement of trace fear conditioning in adolescent rats (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883309/
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system (full–2013) http://ijnp.oxfordjournals.org/content/16/6/1407.long
The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830591/
Effects of Acute Stress on Cardiac Endocannabinoids, Lipogenesis, and Inflammation in Rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988664/
Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924526/
Endocannabinoid Signaling in Hypothalamic-Pituitary-Adrenocortical Axis Recovery Following Stress: Effects of Indirect Agonists and Comparison of Male and Female Mice (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929302/
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870889/
top
Amygdala FAAH and anandamide: mediating protection and recovery from stress (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169112/
Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23433741
Distress, Coping, and Drug Law Enforcement in a Series of Patients Using Medical Cannabis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23538974
Emotional, endocrine and brain anandamide response to social challenge in infant male rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23660109
Cannabinoids and glucocorticoids modulate emotional memory after stress (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23954749
Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24037493
Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT₁A receptor (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23041353
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation (full–2014) http://www.nature.com/tp/journal/v4/n7/full/tp201453a.html
Effects of chaiyuwendan decoction on endocannabinoids levels in adipose tissue of rats with chronic stress-induced depression (full–2014) http://www.journaltcm.com/modules/Journal/contents/stories/141/16.pdf
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates (full–2014) http://www.futuremedicine.com/doi/full/10.2217/pgs.14.151
Cannabis use and anxiety: is stress the missing piece of the puzzle? (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241884/
Chronic stimulation of the tone of endogenous anandamide reduces cue – and stress induced relapse in rats (full–2014) http://ijnp.oxfordjournals.org/content/18/1/pyu025.long
Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25100669
Differential Expression of Brain Cannabinoid Receptors between Repeatedly Stressed Males and Females may Play a Role in Age and Gender-Related Difference in Traumatic Brain Injury: Implications from Animal Studies (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25221540
Cannabinoid Modulation of Amygdala Subregion Functional Connectivity to Social Signals of Threat (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25548107
Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization at Central Amygdala Glutamatergic Synapses (abst–2014)  http://www.cell.com/neuron/abstract/S0896-6273%2814%2900017-8
Regulatory role of the Cannabinoid-2 receptor in stress-induced neuroinflammation in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24467609
Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB (abst–2014) http://onlinelibrary.wiley.com/doi/10.1111/jnc.12716/abstract
Stress regulates endocannabinoid-CB1 receptor signaling (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24882055
top
Epigenetic Regulation of Genes that Modulate Chronic Stress-induced Visceral Pain in the Peripheral Nervous System (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25263804
Endocannabinoid Signaling within the Basolateral Amygdala Integrates Multiple Stress Hormone Effects on Memory Consolidation. (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397407/
Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion (full – 2014) http://www.nature.com/tp/journal/v4/n9/full/tp201477a.html
Endocannabinoid-mediated retrograde modulation of synaptic transmission (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24747340
Endocannabinoids and energy homeostasis: An update (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24752980
Cannabinoids and schizophrenia: therapeutic prospects (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/23829368
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24861565
Strain- and context-dependent effects of the anandamide hydrolysis inhibitor URB597 on social behavior in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24933531
Cannabinoid receptor CB2 prevents development of heart failure in a murine model of pressure overload (abst–2014) http://www.freedomwares.ca/p80cannabinoid-receptor-cb2-prevents-development-heart-failure-murine_model-pressure-overload/
Cannabinoids, endocannabinoids and stress (abst–2014) http://onlinelibrary.wiley.com/doi/10.1002/9781118451281.ch5/summary
Impact of Stress on Prefrontal Glutamatergic, Monoaminergic and Cannabinoid Systems (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25048388
MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25111814
Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25106694
Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25083571
Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/hipo.22344/full
Increased contextual fear conditioning in iNOS knockout mice: additional evidence for the involvement of nitric oxide in stress-related disorders and contribution of the endocannabinoid system (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25618404
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity (full–2015) http://ijnp.oxfordjournals.org/content/early/2015/09/04/ijnp.pyv095.long
Targeting the endocannabinoid system to treat anxiety-related disorders (full–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0058/jbcpp-2015-0058.xml
Cannabis–the Israeli perspective (full–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0091/jbcpp-2015-0091.xml
top
Corticotropin-Releasing Hormone Drives Anandamide Hydrolysis in the Amygdala to Promote Anxiety (full-2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348185/
Developmental regulation of fear learning and anxiety behavior by endocannabinoids (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/gbb.12253/full
Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25960036
Chronic Stress Induces Anxiety via an Amygdalar Intracellular Cascade that Impairs Endocannabinoid Signaling (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25754825
The endocannabinoid system in guarding against fear, anxiety and stress (full–2015) http://www.europeanneuropsychopharmacology.com/article/S0924-977X(15)00364-8/fulltext
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25572435
Training-Associated Emotional Arousal Shapes Endocannabinoid Modulation of Spatial Memory Retrieval in Rats (full–2015) http://www.jneurosci.org/content/35/41/13962.long
Mechanisms of stress in the brain (abst–2015) http://www.nature.com/neuro/journal/v18/n10/full/nn.4086.html
Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. (full – 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700831/
Diet-induced changes in n-3 and n-6 derived endocannabinoids and reductions in headache pain and psychological distress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25958314
Neurobiological Interactions Between Stress and the Endocannabinoid System (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26068727
CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26455361
Endocannabinoid signaling in the stress response of male and female songbirds (link to PDF–2015) http://press.endocrine.org/doi/10.1210/en.2015-1425?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&
Inhibition of anandamide hydrolysis enhances noradrenergic and GABAergic transmission in the prefrontal cortex and basolateral amygdala of rats subjected to acute swim stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25581607
Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25641667
Acute administration of a cannabinoid CB1 receptor antagonist impairs stress-induced antinociception in fish (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25656689
Cannabinoids & Stress: Impact of HU-210 on behavioral tests of anxiety in acutely stressed mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25707713
Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25701682
Interaction of cannabinoid receptor 2 and social environment modulates chronic alcohol consumption (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25827923
Antidepressant-like Effects of Oleoylethanolamide in a Mouse Model of Chronic Unpredictable Mild Stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25864425
Repeated forced swim stress differentially affects formalin-evoked nociceptive behaviour and the endocannabinoid system in stress normo-responsive and stress hyper-responsive rat strains (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25988529
Evidence against a critical role of CB1 receptors in adaptation of the hypothalamic pituitary-adrenal axis and other consequences of daily repeated stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26092203
Stress-related synaptic plasticity in the hypothalamus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26087679
top
Use and effects of cannabinoids in military veterans with posttraumatic stress disorder (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26195653
Cannabinoids and Glucocorticoids in the Basolateral Amygdala Modulate Hippocampal Accumbens Plasticity after Stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26289146
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26361059
Abnormalities in neuroendocrine stress response in psychosis: the role of endo-cannabinoids (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26370602
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26391492
Chronic stress and peripheral pain: Evidence for distinct, region-specific changes in visceral and somatosensory pain regulatory pathways (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408049
Inhibition of anandamide hydrolysis dampens the neuroendocrine response to stress in neonatal rats subjected to suboptimal rearing conditions (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26552023
Maternal separation and early stress cause long-lasting effects on dopaminergic and endocannabinergic systems and alters dendritic morphology in the nucleus accumbens and frontal cortex in rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26539755
Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26609670
Endocannabinoid Regulation of Neuroendocrine Systems (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26638767
The Role of the Brain’s Endocannabinoid System in Pain and Its Modulation by Stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26638768
Stress and memory: A selective review on recent developments in the understanding of stress hormone effects on memory and their clinical relevance (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26708929
Endocannabinoid signaling integrates multiple stress hormone effects on memory (abst–2015) http://www.psyneuen-journal.com/article/S0306-4530%2815%2900634-4/abstract
Being the Victim of Violence during a Date predicts Next-Day Cannabis Use among Female College Students (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26449928
Mediating processes between stress and problematic marijuana use (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25661989
The maternal deprivation animal model revisited (abst–2015) http://www.sciencedirect.com/science/article/pii/S0149763415000172
Correlations between the Memory-Related Behavior and the Level of Oxidative Stress Biomarkers in the Mice Brain, Provoked by an Acute Administration of CB Receptor Ligands (full–2016) http://www.hindawi.com/journals/np/2016/9815092/
2-arachidonoylglycerol signaling impairs short-term fear extinction (full–2016) http://www.nature.com/tp/journal/v6/n3/full/tp201626a.html
Cannabis use among Navy personnel in Sri Lanka: a cross sectional study (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794863/
Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses (full–2016) http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201622a.html
Impaired Ethanol-Induced Sensitization and Decreased Cannabinoid Receptor-1 in a Model of Posttraumatic Stress Disorder (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155759
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology (full–2016) https://elifesciences.org/content/5/e14137
Orexins contribute to restraint stress-induced cocaine relapse by endocannabinoidmediated disinhibition of dopaminergic neurons (full–2016) http://www.nature.com/ncomms/2016/160722/ncomms12199/full/ncomms12199.html
Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress (full–2016) http://www.cell.com/cell-reports/fulltext/S2211-1247(16)30851-8
Endocannabinoid signaling in social functioning: an RDoC perspective (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
Cannabis craving in response to laboratory-induced social stress among racially diverse cannabis users: The impact of social anxiety disorder (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147424/
Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood (full–2016) http://learnmem.cshlp.org/content/23/7/349.long
Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans (full–2016) http://www.psyneuen-journal.com/article/S0306-4530(16)30715-6/fulltext
Bidirectional Effects of Cannabidiol on Contextual Fear Memory Extinction (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00493/full
Getting into the weed: the role of the endocannabinoid system in the brain-gut axis. (link to full via ELSEVIER – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27133395
top
Role of hypothalamic cannabinoid receptors in post-stroke depression in rats (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26778127
Reductions in circulating endocannabinoid 2-arachidonoylglycerol levels in healthy human subjects exposed to chronic stressors (abst–2016) http://www.sciencedirect.com/science/article/pii/S0278584616300045
Chronic alcohol exposure disrupts CB1 regulation of GABAergic transmission in the rat basolateral amygdala (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26786379
Social defeat leads to changes in the endocannabinoid system; an overexpression of calreticulin and motor impairment in mice (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26815100
Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function (abst–2016) http://www.psyneuen-journal.com/article/S0306-4530%2816%2930003-8/abstract
The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26809457
Endocannabinoids in Cerebrovascular Regulation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26825517
Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0028390816300545
Sex differences in hippocampal response to endocannabinoids after exposure to severe stress. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26928784
Effects of the antipsychotic paliperidone on stress-induced changes in the endocannabinoid system in rat prefrontal cortex. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26987678 Pharmacological inhibition of FAAH activity in rodents: a promising pharmacological approach for psychological – cardiac comorbidity? (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0149763416300318
Childhood Maltreatment in the Migraine Patient. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27194425
Activation of cannabinoid CB1 receptors in the ventral hippocampus improved stressinduced amnesia in rat. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27282634
Exercise as an adjunctive treatment for cannabis use disorder. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27314543
Docosahexaenoic acid attenuates in endocannabinoid synthesis in RAW 264.7 macrophages activated with benzo(a)pyrene and lipopolysaccharide. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0378427416301667
Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and (+/+) mice. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27385208
Acute effects of cannabis on breath-holding duration. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27454678 Understanding resilience: New approaches for preventing and treating PTSD. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27417856
Involvement of endocannabinoid neurotransmission in the bed nucleus of stria terminalis in cardiovascular responses to acute restraint stress in rats. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27441413
Endocannabinoids control vesicle release mode at midbrain periaqueductal grey inhibitory synapses. (abst – 2016) http://onlinelibrary.wiley.com/doi/10.1113/JP272292/abstract
Acute Stress Suppresses Synaptic Inhibition and Increases Anxiety via Endocannabinoid Release in the Basolateral Amygdala. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27511017
Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0278584616301269
Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27528659
Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27551883
Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27568641
FAAH Gene Variation Moderates Stress Response and Symptom Severity in Patients with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27716956
Chronic stress leads to epigenetic dysregulation of neuropeptide-Y and cannabinoid CB1 receptor in the mouse cingulate cortex. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0028390816304580
Variants in the CNR1 gene predispose to headache with nausea in the presence of life stress. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27762084
Older marijuana users: Life stressors and perceived social support. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27776245
Anxiety Sensitivity and Distress Intolerance as Predictors of Cannabis Dependence Symptoms, Problems, and Craving: The Mediating Role of Coping Motives. (abst – 2016) http://www.jsad.com/doi/10.15288/jsad.2016.77.889
Regulation of fear extinction by long-term depression: the roles of endocannabinoids and brain derived neurotrophic factor. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27867101
Cannabimimetic phytochemicals in the diet – an evolutionary link to food selection and metabolic stress adaptation? (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27891602
Sex-dependent influence of chronic mild stress (CMS) on voluntary alcohol consumption; study of neurobiological consequences. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0091305716302465
Identification of an endocannabinoid system in the rat pars tuberalis-a possible interface in the hypothalamic-pituitary-adrenal system? (abst – 2016) http://link.springer.com/article/10.1007%2Fs00441-016-2544-1
Endocannabinoid Signaling and the Hypothalamic-Pituitary-Adrenal Axis. (abst – 2017) https://www.ncbi.nlm.nih.gov/pubmed/28134998


STORAGE of CANNABIS
The stability of cannabis and its preparations on storage (abst–1976) http://www.ncbi.nlm.nih.gov/pubmed/6643
The decomposition of acidic and neutral cannabinoids in organic solvents (abst–1977) http://www.ncbi.nlm.nih.gov/pubmed/17692
Constituents of Cannabis sativa L. XIII: Stability of dosage form prepared by impregnating synthetic (–)-delta 9-trans-tetrahydrocannabinol on placebo Cannabis plant material (abst–1978) http://www.ncbi.nlm.nih.gov/pubmed/660481
Stability of Cannabis sativa L. samples and their extracts, on prolonged storage in Delhi (abst–1978) http://www.ncbi.nlm.nih.gov/pubmed/258607
Stability of Cannabinoids in Dried Samples of Cannabis Dating from Around 1896-1905 (abst–1990) http://www.ncbi.nlm.nih.gov/pubmed/2314109
Temperature and Moisture Content for Storage Maintenance of Germination Capacity of Seeds of Industrial Hemp, Marijuana, and Ditchweed Forms of Cannabis sativa. (abst – 2012) http://www.agr.gc.ca/eng/abstract/?id=25355000000564
Determination of the relative percentage distribution of THCA and Δ9-THC in herbal cannabis seized in Austria – Impact of different storage temperatures on stability (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26247127
Storage and disposal of medical cannabis among patients with cancer: Assessing the risk of diversion and unintentional digestion (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27420392
Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00285/full#B14
Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method (abst–2016) http://www.sciencedirect.com/science/article/pii/S0731708516302722
Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27798074


STROKE
The cannabinoid WIN55212-2 promotes neural repair after neonatal hypoxia-ischemia (full–2010) http://stroke.ahajournals.org/content/41/12/2956.long
The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20875047
The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration. (full-2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2010.00195.x/full
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke (link to PDF–2010) http://www.mdpi.com/1424-8247/3/7/2197
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment (full–2010) http://www.fasebj.org/content/24/3/788.long
top
The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic ischemic brain damage in mice is mediated by CB(2) and adenosine receptors (abst–2010) http://www.unboundmedicine.com/medline/ebm/record/19900555/abstract/The_neuroprotective_effect_of_cannabidiol_in_an_in_vitro_model_of_newborn_hypoxic_ischemic_brain_damage_in_mice_is_mediated_by_CB_2__and_adenosine_receptors_
Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia ischemia in newborn pigs (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21654550
Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21470162/abstract/Targeting_the_Endocannabinod_System_to_Limit_Myocardial_and_Cerebral_Ischemic_and_Reperfusion_Injury_
Cannabinoid receptor type 2 activation yields delayed tolerance to focal cerebral ischemia (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21443454
Residual effects of focal brain ischaemia upon cannabinoid CB(1) receptor density and functionality in female rats (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21145311
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22352284
Contribution of Hypothermia and CB(1) Receptor Activation to Protective Effects of TAK-937, a Cannabinoid Receptor Agonist, in Rat Transient MCAO Model (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397930/?tool=pubmed
Update on the role of cannabinoid receptors after ischemic stroke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337695/?tool=pubmed
Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection (full–2012) http://stroke.ahajournals.org/content/43/1/211.long
Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446851/
Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02042.x/pdf
Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretion (full–2012) http://www.jneuroinflammation.com/content/9/1/76
WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23202804
WIN55, 212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1/2 via cannabinoid receptor 1 after stroke-induced demyelination (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23202804
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities (full–2012) http://rstb.royalsocietypublishing.org/content/367/1607/3353.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22119394
top
The Cannabinoid WIN 55212-2 Mitigates Apoptosis and Mitochondrial Dysfunction After Hypoxia Ischemia (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/21909954
Effects of cannabinoid receptor agonist WIN 55,212-2 on blood-brain barrier disruption in focal cerebral ischemia in rats (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22678129
The Role of Cannabinoids In Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22420307
Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor α (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22480617
Cannabinoid Receptor Subtypes 1 and 2 Mediate Long-Lasting Neuroprotection and Improve Motor Behaviour Deficits After Transient Focal Cerebral Ischemia (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23069763
A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury (abst–2012) http://www.sciencedirect.com/science/article/pii/S1043661812001636
Molecular targets underlying SUMO-mediated neuroprotection in brain ischemia (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/jnc.12347/full
Is the cardiovascular system a therapeutic target for cannabidiol? (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04351.x/full
Drug-Induced Hypothermia in Stroke Models: Does it Always Protect? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081530/
Activation of Cannabinoid CB2 Receptor-Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury (full–2013) http://ajp.amjpathol.org/article/S0002-9440%2812%2900890-5/fulltext
Ischemic stroke after use of the synthetic marijuana “spice” (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863350/
The neuroprotective effects of cocoa flavanol and its influence on cognitive performance (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575938/
Does smoking marijuana cause stroke? (article–2013) http://www.thepoisonreview.com/2013/01/26/does-smoking-marijuana-cause-stroke/
Nicotine-Induced Neuroprotection Against Ischemic Injury Involves Activation of Endocannabinoid System in Rats (abst–2013) http://link.springer.com/article/10.1007/s11064-012-0927-6
Activation of STAT3 is involved in neuroprotection by electroacupuncture pretreatment via cannabinoid CB1 receptors in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23880371
Acupuncture therapy for stroke patients (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24215922
Effect of cannabinoid CB2 receptor agonism on learning and memory in a mouse model of photothrombosis (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.4?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: Therapeutic time window, combination with t-PA and efficacy in aged rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23791950
Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review  (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23829360
Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/22371074
Synthetic Cannabis and Acute Ischemic Stroke (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24119618
Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24323810
top
‘Legal high’ associated Wallenberg syndrome (abst–2013) http://casereports.bmj.com/content/2013/bcr-2013-009693.abstract?sid=0550787d-e463-41b1-bac9-0d2bad5504d9
Cannabinoids: well-suited candidates for the treatment of perinatal brain injury (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061885/
Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases (link to PDF–2014) http://www.mdpi.com/1420-3049/19/11/18781
Hypoximimetic activity of N-acyl-dopamines. N-arachidonoyl-dopamine stabilizes HIF-1α protein through a SIAH2-dependent pathway (full–2014) http://www.sciencedirect.com/science/article/pii/S0167488914002821
Cannabinoids in experimental stroke: a systematic review and meta-analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25492113
The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24721671
Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24874648
Severe rhabdomyolysis and intracranial hemorrhage associated with synthetic cannabinoid: a case report (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25179201
A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25241766
Mn-SOD Upregulation by Electroacupuncture Attenuates Ischemic Oxidative Damage via CB1R-Mediated STAT3 Phosphorylation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25432886
Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24532152
Magnolol protects neurons against ischemia injury via the downregulation of p38/MAPK, CHOP and nitrotyrosine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25038313
Glycogen synthase kinase-3β is involved in electroacupuncture pretreatment via the cannabinoid CB1 receptor in ischemic stroke (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/23943518
Endocannabinoids modulate human blood-brain barrier permeability in vitro (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13106/full
Involvement of GluR2 up-regulation in neuroprotection by electro-acupuncture pretreatment via cannabinoid CB1 receptor in mice (full–2015) http://www.nature.com/srep/2015/150330/srep09490/full/srep09490.html
Time-Dependent Protection of CB2 Receptor Agonist in Stroke (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132487
Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141600
top
Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558292/
Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516969/
Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Pre-clinical Models to Clinical Applications (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26260390
A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26032254
A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552583/
Cannabinoid receptor type 1 agonist ACEA improves motor recovery and protects neurons in ischemic stroke in mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26296704
Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 suppress chronic cerebral hypoperfusion-induced neuronal apoptosis by inhibiting c-Jun N-terminal kinase signaling (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25795598
Protective effect of paeoniflorin on the hippocampus in rats with cerebral ischemia reperfusion through activating cannabinoid receptor 2 (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25854559
The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25936364
N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26055231
Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26238742
Neuroprotective mechanisms of cannabinoids in brain ischemia and neurodegenerative disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26299059
Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26343919
Endocannabinoids and the Cardiovascular System in Health and Disease (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408169
A pathophysiological role of TRPV1 in ischemic injury after transient focal cerebral ischemia in mice. (abst – 2015) http://www.sciencedirect.com/science/article/pii/S0006291X15307270
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation (full – 2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00264/full
Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. (full – 2016) http://www.sciencedirect.com/science/article/pii/S221323171630338X
Role of hypothalamic cannabinoid receptors in post-stroke depression in rats abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26778127
Mn-SOD Upregulation by Electroacupuncture Attenuates Ischemic Oxidative Damage via CB1R-Mediated STAT3 Phosphorylation (abst–2016) http://link.springer.com/article/10.1007/s12035-014-8971-7
Prior Cannabis Use Is Associated with Outcome after Intracerebral Hemorrhage (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26820826
Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26215450
Endocannabinoids in Cerebrovascular Regulation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26825517
top
Arachidonyl-2-Chloroethylamide Alleviates Cerebral Ischemia Injury Through Glycogen Synthase Kinase-3β-Mediated Mitochondrial Biogenesis and Functional Improvement (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26820679
Sevoflurane Prevents Stroke-induced Depressive and Anxiety Behaviors by Promoting Cannabinoid Receptor Subtype I-dependent Interaction Between β-Arrestin 2 and ERK1/2 in the Rat Hippocampus. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26991409
Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27117865
Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27142423
Pharmacological hypothermia: a potential for future stroke therapy? (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27320243
Ischemic Stroke, Excitatory Amino Acids Toxicity and the Adjustment of Acupuncture Intervention (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27323449 Endocannabionoid System in Neurological Disorders. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27364363
The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0304394016305353
Expression of the Endocannabinoid Receptor 1 in Human Stroke: An Autoptic Study. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27425766
Repeated Thrombosis After Synthetic Cannabinoid Use. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27595371
Acute Effects of Synthetic Cannabinoids: Update 2015. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27715709
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0149763416304390 Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. (abst – 2016) http://www.sciencedirect.com/science/article/pii/S0278584616302524
Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/27899748
URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/28042028
Cannabis, Tobacco, Alcohol Use, and the Risk of Early Stroke: A Population-Based Cohort Study of 45 000 Swedish Men. (abst – 2016) https://www.ncbi.nlm.nih.gov/pubmed/28028147
Involvement of the endocannabinoid system in the physiological response to transient common carotid artery occlusion and reperfusion. (abst – 2017) https://www.ncbi.nlm.nih.gov/pubmed/28103941


SUICIDE
Mixed mood disorder (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/228/?pagenum=2
Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878847/
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21497918
High on Life? Medical Marijuana Laws and Suicide (full–2012) http://ftp.iza.org/dp6280.pdf
Suicidal ideation and self-harm following K2 use (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23304900
Does the legalization of medical marijuana increase completed suicide? (full–2014) http://informahealthcare.com/doi/full/10.3109/00952990.2014.910520
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates (full–2014) http://www.futuremedicine.com/doi/full/10.2217/pgs.14.151
Medical Marijuana Laws and Suicides by Gender and Age (abst–2014) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2013.301612?journalCode=ajph
Cannabis use and suicidal ideations in high-school students (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25123343
Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26253623
A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26331953
Endocannabinoids and Mental Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408164
top
Cannabis for posttraumatic stress disorder: A neurobiological approach to treatment (full–2016) http://journals.lww.com/tnpj/Fulltext/2016/01000/Cannabis_for_posttraumatic_stress_disorder__A.6.aspx
Dose of Reality: The Effect of State Marijuana Legalizations (report–2016) http://www.cato.org/publications/policy-analysis/dose-reality-effect-state-marijuana-legalizations#full
Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26890319
A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27314752


SYSTEMIC MASTOCYTOSIS
Systemic mastocytosis and medical marijuana (case report- undated) http://cannabisclinicians.org/view-all-case-reports/entry/645/


SYSTEMIC SCLEROSIS
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893662/
Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis (full–2010) http://onlinelibrary.wiley.com/doi/10.1002/art.27642/full
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22033526
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22492781
Pathogenesis of Systemic Sclerosis (full–2015) http://journal.frontiersin.org/article/10.3389/fimmu.2015.00272/full
Can Cannabinoids Modulate Fibrotic Progression in Systemic Sclerosis? (link to PDF–2016) http://www.ima.org.il/imaj/ViewArticle.aspx?aId=3850
Medical Cannabis – another piece in the mosaic of autoimmunity? (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27859024